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ABSTRACT 
Prostate cancer, with an estimated 1.3 million new cases and 360,000 deaths every 
year, affects elderly men worldwide. Prostate cancer can either develop slowly 
without symptoms or aggressively by quickly disseminating the disease. To move, 
cancer cells need to adhere to the extracellular matrix (ECM) and this is crucial for 
the development of metastases. Prostate cancer cells metastasize mainly to nearby 
organs and to the bones, where the tissue microenvironment is mainly built by 
collagens. The stem cell-like cells in prostate cancer are known to express high 
levels of integrin α2β1, a collagen receptor. Here we studied the role of integrin 
α2β1 in the motility, survival and signaling of prostate cancer cells. In addition, we 
analyzed the ECM in the prostate and also the matrix produced by prostate-derived 
primary fibroblasts in vitro using mass spectrometry and proteomics. 
This thesis consists of work published in two separate articles and one 
manuscript. The first part focuses on the role of integrin α2β1 in prostate cancer 
cells. In the study DU145 cells were treated with the cytotoxic drug docetaxel and 
analyzed by flow cytometry. Cell sorting, genome editing with CRISPR/ Cas9 and 
RNA sequencing were also used. In addition, 3D cell culture, migration and 
invasion assays were used throughout the study. The second part of this thesis 
focuses on the ECM of the human prostate. Surgically removed prostates were 
used to extract ECM proteins, which were analyzed by mass spectrometry to study 
the molecular composition of the matrix. Prostate tissue was also used to isolate 
primary fibroblasts. The fibroblasts were propagated in cell culture to study their 
influence on DU145 and PC3 prostate cancer cells in vitro. Using this approach we 
were able to study the ECM produced solely by fibroblasts or in co-culture with 
cancer cells. We also investigated further the effect of fibroblasts and the ECM on 
cancer cell motility and observed that fibroblasts induce DU145 cancer cell 
invasive capability and in co-culture enhance ECM synthesis and its active 
remodeling. 
In conclusion, this thesis showed that α2β1 integrin is essential for cancer cell 
dissemination. In addition integrin α2β1 downregulates the proliferation of prostate 
cancer cells and due to this selection pressure favors the α2β1low/negative daughter 
cells of the stem cell like cells. The ECM is synthesized mainly by fibroblasts and 
the active rearrangement of the ECM is regulated by fibroblast-cancer cell 
crosstalk. 
KEYWORDS: prostate cancer, extracellular matrix, fibroblasts, integrin α2β1, 
invasion  
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TIIVISTELMÄ 
Eturauhassyöpä on yleinen, pääasiassa iäkkäiden miesten tauti. Eturauhassyöpä voi 
olla hidas ja oireettomasti etenevä, tai nopeasti etenevä ja etäpesäkkeitä 
muodostava sairaus. Jotta syöpäsolut voisivat liikkua ja muodostaa etäpesäkkeitä, 
niiden on sitouduttava soluväliaineeseen kollageenireseptori-integriinin välityk-
sellä. Eturauhassyöpä muodostaa etäpesäkkeitä pääasiassa eturauhasen lähellä 
oleviin elimiin ja luuhun, jossa solujen mikroympäristö sisältää paljon kollageenia. 
Eturauhassyövän kantasolukaltaiset solut ilmentävät runsaasti kollageenireseptori 
α2β1-integriiniä. Tässä työssä olen tutkinut α2β1-integriinin roolia eturauhas-
syövän solujien liikkumisessa, elonjäämisessä ja signaloinnissa. Lisäksi, eturauha-
sen soluväliainetta ja eturauhasesta eristettyjen fibroblastien tuottamaa soluväli-
ainetta tutkittiin proteomiikan menetelmillä. 
Väitöskirjatutkimukseni koostuu kolmesta osatyöstä, joista kaksi on julkaistu 
kansanvälisissä tieteellisissä julkaisuissa ja viimeinen osatyö on käsikirjoitus. 
Ensimmäisessä osatyössä keskityttiin α2β1-integriinin rooliin eturauhassyöpä-
soluissa. Työssä käytettiin yleisesti saatavilla olevia eturauhassyövän etäpesäkkeisis-
tä eristettyjä solulinjoja DU145 ja PC3, joita käsiteltiin doketakseli syöpälääkkeellä. 
Tutkimusmenetelminä käytettiin virtaussytometriaa, genomin muokkausta 
CRISPR/Cas9-menetelmällä sekä RNA-sekvensointia. Lisäksi koko väitöskirjatyössä 
käytettiin metodeina 3D-soluviljelyä ja solusferoidien migraatio- ja invaasiokokeita. 
Toisessa osatyössä keskityttiin eturauhasen soluväliaineeseen. Sitä tutkittiin 
eristämällä soluvälinaineen proteiineja kirurgisesti poistetuista eturauhasista ja 
analysoimalla soluväliaineen koostumusta massaspektrometrian avulla. Eturauhasista 
myös eristettiin fibroblasteja ja tutkittiin niiden vaikutusta DU145- ja PC3-
syöpäsoluihin. Näin oli mahdollista analysoida sekä fibroblastien yksin tuottamaa 
soluväliainetta että niiden yhteisviljelmissä syöpäsolujen kanssa tuottamaa 
soluväliainetta. Lisäksi tutkimme fibroblastien ja soluvälinaineen vaikutusta 
syöpäsolujen liikkuvuuteen. Tuloksemme osoittavat, että yhteisviljelmissä 
syöpäsolujen kanssa fibroblastit lisäävät syöpäsolujen liikkuvuutta ja lisäksi 
soluväliaineen tuotanto ja sen muokkaus lisääntyy.  
Yhteenvetona väitöskirjatyön tulokset osoittavat, että α2β1-integriinin 
ilmentyminen on tärkeää eturauhassyöpäsolujen liikkumiselle. Lisäksi osoitimme 
α2β1-integriinin hidastavan solujen jakaantumista, mikä selittää α2β1-integriinin 
vähäisen määrän kantasolujen kaltaisten solujen tytärsoluissa. Pääasiassa 
fibroblastit tuottavat eturauhasyövän soluväliaineen ja sen aktiivinen muokkaa-
minen tapahtuu syöpäsolujen ja fibroblastien yhteisvaikutuksesta. 
AVAINSANAT: eturauhassyöpä, α2β1-integriini, soluväliaine, invaasio, fibroblastit  
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ABSTRAKT 
Iga aastal haigestub 1.3 miljonit ja sureb 360 000 meest eesnäärmevähi tõttu üle 
maailma. See on üks sagedamaid vähkkasvajaid meestel, millesse haigestumise risk 
kasvab vanusega. Eesnäärmevähi progresseerumine võib olla aeglane ilma 
sümptomiteta või vastupidiselt agressiivne ja kiiresti metastaseeruv. Eesnäärmevähk 
levib peamiselt lähedal asuvatesse organitesse, aga ka luudesse, mis koosnevad 
peamiselt kollageenist. Vähirakud kinnituvad rakuvaheainele ehk ekstratsellulaarsele 
maatriksile, see on vajalik nende rakkude liikumiseks kudede siseselt ning metastaaside 
moodustamiseks. Varasematest teadustöödest on teada, et eesnäärme tüvirakud 
ekspresseerivad palju kollageeni retseptorit - α2β1 integriini. Käesolevas töö peamine 
eesmärk oli uurida α2β1 integriini rolli eesnäärmevähi rakkude liikumises, elulemuses 
ja signaaliseerimises. Teiseks töö uurimisobjektiks oli rakuvaheaine: nii eesnäärmes in 
vivo toodetud rakuvaheaine, kui ka koest eraldatud fibroblastide poolt koekultuuris 
toodetud ekstratsellulaarne maatriks.  
Käesolev doktoritöö koosneb kahest artiklist, mis on avaldatud rahvusvaheliselt 
tunnustatud teadusajakirjades ja ühest käsikirjast. Doktoritöö esimene osa baseerub 
α2β1 integriini uurimisel kommertsiaalses eesnäärmevähi rakuliinis DU145. 
Põhilisteks rakendatud meetodideks olid DU145 rakkude käsitlemine tsütotoksilise 
ravimiga Docetaxel, läbivoolu tsütomeetria analüüs, rakkude sorteerimine, genoomse 
DNA modifitseerimine CRISPR/Cas9 süsteemi abil ja RNA-sekvenseerimine. Lisaks 
eelnevale on kogu töös kasutatud 3D rakukultuuri, migratsiooni ja invasiooni 
eksperimente. Töö teine osa keskendub inimese eesnäärme rakuvaheaine koostise 
uurimisele. Selleks analüüsisin inimese eesnäärme koest isoleeritud ekstratsellulaarse 
maatriksi molekulaarset koostist mass spektromeetria abil. Täiendavalt uurisin in 
vitro süsteemis eesnäärme koest eraldatud fibroblastide rakuvaheaine tootmist üksi ja 
koos DU145 või PC3 vähi rakkudega. Lisaks uurisin põhjalikult fibroblastide ja 
rakuvaheaine mõju vähirakkude liikumisvõimele. Tulemuste põhjal võib väita, et 
fibroblastid mõjutavad positiivselt DU145 vähirakkude liikumist kollageenist geelis. 
Lisaks toimub ko-kultuuris rohke maatriksi valkude tootmine ning nende aktiivne 
remodelleerimine. 
Kokkuvõtvalt, käesolev doktoritöö näitab, et integriin α2β1 on vajalik 
eesnäärmevähi vähirakkude liikumiseks ja samas vähendab rakkude jagunemist, 
seetõttu enamikes vähirakkudes ekspressioon väheneb. Eesnäärme rakuvaheaine on 
põhiliselt toodetud fibroblastide poolt ja selle aktiivne remodelleerimine toimub 
fibroblastide ja vähirakkude koostööna. 
MÄRKSÕNAD: eesnäärmevähk, α2β1 integriin, rakuvaheaine, invasioon, 
fibroblastid 
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1 Introduction 
Adenocarcinoma of the prostate is a common cancer type in elderly men. The 
aggressive form of the disease, called castration-resistant prostate cancer (CRPC), 
has limited treatment options and remains incurable. One of the main mechanisms 
of invasive, treatment-resistant malignancies is suspected to be the existence of 
cancer stem-like cells (CSCs). Prostate tissue stem cells and also CSCs can be 
identified using integrin α2β1. However, the expression of integrin α2β1 has been 
shown to disappear in high Gleason score cases, especially in poorly differentiated 
adenocarcinomas with high Gleason score (Mirtti et al., 2006). As α2β1 integrin is 
a collagen receptor, one would assume that ECM, especially the collagenous 
matrix is important for CSCs. 
The purpose of this study was to investigate the role of integrin α2β1 in 
prostate cancer. More specifically, the effect of integrin α2β1 on DU145 cell 
proliferation, motility, drug resistance and gene expression was analyzed by 
genomically alterating integrin α2. In addition matrisome of human prostate tissue 
was studied using mass spectrometry to determine possible ligands for integrin 
α2β1 in prostate ECM. For in vitro studies, human primary prostate fibroblast cells 
were isolated and primary cell lines were created. Matrisome of primary human 
fibroblasts, DU145 and PC3 cancer cells were studied in an individual and in a co-
culture system.  
  13 
2 Review of the Literature 
2.1 Prostate tissue cellular organization 
Prostate tissue contains epithelial acini surrounded by fibromuscular stroma. The 
epithelial compartment of the mature prostate consists of several cell types: 
differentiated luminal cells, which form the major cell type (60% of epithelial 
cells) and are responsible for the secretory properties producing seminal fluid; 
basal cells (40% of epithelial cells), and rare neuroendocrine cells that are present 
in both the luminal and basal cell layers. Basal cells reside on the basement 
membrane (BM) and can be divided into 3 sub-populations: stem cells (SC), transit 
amplifying (TA) cells and committed basal cells (BC). Stem cells can give rise to 
transit TA cells, which can further differentiate into non-secretory BC, and these 
are able to differentiate into luminal cells (Figure 1). The first evidence that 
prostate tissue contains non-differentiated progenitor cells came in the 1980s, when 
experiments with rodent prostates showed multiple rounds of castration-induced 
regression and androgen-induced regeneration of prostate tissue (English, Santen, 
and Isaacs 1987). A year later, this idea about progenitor cells was further 
supported by the discoveries that BC express low/undetectable levels of the 
androgen receptor (AR) and are independent of androgens, whereas differentiated 
luminal cells are dependent on AR signaling (Kyprianou and Isaacs 1988).  
In a normal prostate, the highest expression of integrin α2β1 is detectable in 
basal cells, which use it to bind to BM components, including laminins and 
collagen IV. BC differentiation into luminal cells is accompanied by a loss of 
adhesion to the basal membrane and a decrease in integrin α2β1 expression. At the 
same time, the increased expression of AR in luminal cells supports the idea that in 
a normal prostate cell, adhesion to the BM and the expression of AR are separated 
to different cell layers. Adhesion to the BM facilitates survival and proliferation 
through the transduction of stromal signals, whereas androgen signaling triggers 
the secretion of protein and maintains the viability of luminal cells (Knudsen and 
Miranti 2006). 
Marjaana Ojalill 
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Figure 1.  Schematic diagram showing the anatomical location of the prostate, tissue 
structure and the cellular composition of prostate epithelium. The prostate, an 
essential part of the male reproductive system, is located in front of the rectum and 
below the bladder. Prostate tissue consists of epithelial ducts and acini surrounded 
by fibromuscular stroma. Prostate epithelium consists of an inner layer of 
differentiated secretory luminal cells. Tissue stem cells (SC), transit amplifying 
(TA) and committed basal cells (BC) reside continuously around luminal cells in 
contact with the basement membrane. Neuroendocrine cells and intermediate cell 
(expressing both BC and luminal cell markers) are located on both layers. Modified 
from https://www.flickr.com/photos/ nihgov/25137782099/ and Rybak et al., 2015 . 
More recently it was shown in developmental studies, that cells expressing basal 
progenitor marker p63 could develop the entire epithelial cell compartment, with 
both basal and luminal cells. This suggests that in adult tissue, p63-positive cells 
may also represent progenitor cells that are able to give rise to more differentiated 
cells when necessary due to, for example, tissue injury (Signoretti et al., 2005). 
Murine and human prostates are somewhat different. In rodents, prostate SCs 
are located in the distal region (Kinbara et al., 1996) whereas in human, prostate 
SCs are located randomly throughout the acini and ducts (Collins et al., 2001). It is 
known that SCs are located in a specialized environment, called a niche, which 
supports the balance between quiescence and self-renewal through regulating 
asymmetric cell division. Several cell surface markers have been used to identify 
human prostate stem cells (PSCs), for example, a high expression of integrin α2β1 
on a subset of BCs and rapid adhesion to collagen I (Collins et al., 2001). In 
multiple niches, β1-integrin mediated signaling has been shown to be important. 
For example, in the mammary gland β1-integrin is essential for maintaining the 
Review of the Literature 
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stem cell population and regulating asymmetric division (Taddei et al., 2008). In 
another study, prostate sphere-forming cells were restricted to a basal phenotype 
and shown to express CD44, a receptor for the extracellular matrix component 
hyaluronan, α6 integrin, a laminin receptor, and Trop2 (Garraway et al., 2010). 
CD133, typically expressed by hematopoietic and neural SCs (Yin et al., 1997), has 
been shown to be expressed also by a subset (less than 1%) of prostate BCs. These 
cells generated prostate acini in vivo, consisting of epithelium with both basal and 
luminal cells (Richardson et al., 2004). Conclusively, murine prostate SC could be 
identified based on the expression of p63, Sca-1, CK5, α6 integrin, Trop2, CD133 
(Lawson et al., 2006; Barclay et al., 2008; Tani et al., 2000; Kinbara et al., 1996) 
and human prostate SC based on the surface markers CD44, α2β1 integrinHigh, α6 
integrin, CD133 and Trop2 (Collins et al., 2001; Richardson et al., 2004; 
Yamamoto et al., 2012; Trerotola et al., 2010; Goldstein et al., 2008; Taylor et al., 
2012). 
2.2 Prostate cancer statistics 
The statistics for prostate cancer (PRC) show that it is a major health problem all 
over the world. Globally, PRC is the second most diagnosed cancer, having 
approximately 1.3 million new cases, and the 5th cause of cancer-related deaths in 
men, being responsible for 360,000 deaths per year (Bray et al., 2018). In Finland, 
5,444 new cases were diagnosed in 2017 and the number of PRC-related deaths 
was 912 (cancerregistery.fi, Finnish Cancer Registry). In Europe approximately 
417,000 citizens were diagnosed with PRC and 92,200 men died from the disease 
in 2012. Similarily, figures for the United States in 2018 were 164,690 new cases 
and 29,430 deaths (European Network of Cancer Registries). There is a strong 
likelihood that the high number of new incidences has been influenced by the 
intensive use of prostate specific antigen (PSA) testing. This early detection along 
with diagnostics should lead to a drop in the incidence and prevelence of new cases 
within a few years. 
Most PRCs (about 91%) are discovered at the local stage. These cases have a 
good prognosis, with a 5-year survival rate of almost 100%. To ensure the best 
outcome for patients, it is important to distinguish slow growing cases from 
aggressive carcinomas to avoid overtreatment and intervene with suitable treatment 
as early as possible. To predict the prognosis of the patient clinicians consider the 
stage of the disease, histological Gleason score and the level of PSA. At later 
stages of the disease, when cancer cells have disseminated and formed metastasis 
into other tissues, the treatment is less effective and the 5-year survival rate 
decreases drastically to 30% (Wallace et al., 2014). 
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2.3 Prostate cancer progression and treatment 
Prostate cancer is usually described as a stepwise process, starting from prostate 
intraepithelial neoplasia (PIN), followed by local prostate cancer which is found 
only inside of prostate capsule and locally advanced carcinoma affecting nearby 
organs. Invasive adenocarcinoma, in which cancer cells have disseminated into 
lymph nodes or metastasized into bones finally results in Castration Resistant 
Prostate Cancer (CRPC). The pre-malignant state of prostate cancer, called PIN, is 
described as hyper-proliferation of the prostate epithelial cells. Based on different 
studies, both luminal and basal epithelial cells can give rise to PRC (Taylor et al., 
2012; Wang et al., 2014; Park et al., 2016). Prostate cancer heterogeneity can be 
partially explained by the fact that different cell types within the prostate epithelia 
can be vulnerable to mutations and through this become a cell-of-origin. However, 
most prostate cancers are classified as acinar adenocarcinomas with the luminal 
phenotype characterized by the absence of basal markers p63, cytokeratins 5 and 
14. The less common PRCs include squamous cell carcinoma and small cell 
carcinoma (Humphrey 2012). At the initial stage of prostate adenocarcinoma, the 
BM is destroyed after which malignant tumor cells may directly interact with the 
prostatic stroma. These tumors that lie within the prostate capsule, called local 
prostate cancers, can be treated by radiotherapy or with radical prostatectomy (the 
complete removal of the prostate) and the 5-year survival prognosis for patients is 
almost 100%. Once cancer cells disseminate to nearby organs such as seminal 
vesicles and the rectum the disease is called locally advanced cancer. Metastatic 
prostate cancer disseminates mainly to the bones and to the lymph nodes. Hormone 
therapy is the first choice of treatment for disseminated prostate cancer to inhibit 
the proliferation of malignant cells. Although androgen deprivation therapy reduces 
the size of the tumor and metastatic lesions, with longer treatment periods the 
cancer cells often become androgen independent (Armstrong and Gao 2015). 
Prostate cancer is known to be a very heterogeneous disease (Robinson et al., 
2015). This heterogeneity can be attributed to genomic alterations, such as copy 
number alterations, somatic mutations and DNA rearrangements. As part of the 
patient prognosis, the tumor genomic and micro-environmental heterogeneity 
should be considered and used (Lalonde et al., 2014). Many studies have unveiled 
several mechanisms that explain how cancer cells become androgen independent. 
These mechanisms include mutations in the AR gene or its amplification, ligand 
independent activation of AR by crosstalk with receptor tyrosine kinases (RTKs) 
and unbalanced regulation of co-receptors and -activators (Harris et al., 2009). In 
addition, one possible mechanism is based on cancer stem cells (CSCs) (Collins et 
al., 2005), which are both AR independent and also able to produce subpopulations 
of AR-sensitive and independent clones. This could also explain the heterogeneity 
of cancer cells found in autopsy samples of metastatic prostate cancer (Shah et al., 
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2004). The treatment options for CRPC include microtubule targeting drugs, such 
as the widely used chemotherapeutics docetaxel and cabazitaxel (de Leeuw et al., 
2015). However, cancer cells have mechanisms to develop drug resistance, for 
example by increasing the expression of nuclear factor kappa B (NF-κB) (O’Neill 
et al., 2011) or by increasing the efflux of drugs to the extracellular space mediated 
by multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B 
member 1 (ABCB1) (Armstrong and Gao 2015). Despite the many treatment 
options available to patients, the prognosis for metastatic CRPC is poor, which 
encourages further research aiming to identify new treatment options. 
2.4 Cancer stem cells 
The hypothesis that tumors contain a small population of cells which provide the 
heterogeneity, hierarchical organization and development of treatment-resistant 
disease has shown to be correct for many human malignancies. These cells are 
referred to interchangeably as cancer stem-like cells, tumorigenic cells, cancer 
initiating cells (CICs) or cancer stem cells (CSCs). CSCs were first identified in 
human acute myeloid leukemia (Bonnet and Dick 1997), after which their 
populations have been described in many tumors, for example in the breast (Al-
Hajj et al., 2003), brain (Singh et al., 2004), lung (Ho et al., 2007), skin (Schatton 
et al., 2008) and prostate (Collins et al., 2005). Despite the numerous publications 
characterising the stemness, long survival and self-renewing capability of these 
cells in different cancer types, the stem-like cells in cancer are still controverial, as 
studies do not consistently indicate asymmetric cell-divisions and all other stem 
cell properties. The tumor stem cell model contradicts the stochastic model, which 
proposes that all cells in a tumor could initiate a new tumor, whereas the 
hierarchical model of cancer proposes that only CSCs are tumorigenic (Figure 2A). 
Malignant cells, with stem cell properties display a tumor-promoting ability, are 
able to self-renew during long periods and survive radio- and chemotherapy. 
Overall, CSCs are capable of maintaining tumor homeostasis and of generating 
heterogeneous sub-populations of cancer cells, to drive the progression of disease 
and to initiate metastases. Collectively, stem cells in cancer have enhanced 
plasticity, altered self-renewal and long-term tumorigenic properties.  
The stem cell population in normal tissue is maintained by the balance between 
the renewal and quiescence of the cell. SCs are usually in quiescent state and 
proliferate only in cases of tissue renewal or tissue damage. It has been suggested 
that CSCs share this property, at least partially, which could explain the difficulties 
targetting them and explaining the enrichment of CSCs after chemotherapy. The 
quiescent cells in cancer, also called dormant or persistent cells, are often 
undetectable and can survive for long periods despite treatment. The dormant cells 
share the properties of stem cells, like low cell proliferation and resistance to drugs, 
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which in turn cause the enrichment of these dormant cells during drug treatment 
(Nan et al., 2014). Furthermore, the ability of the CSCs to be dormant or quiescent 
and to resist cytotoxic drugs may explain relapses after initially successful 
treatment (Figure 2B), even decades after the removal of a primary tumor. The 
dormant cells are not active in the cell cycle, instead they have been shown to 
remain in G0/G1 state (Touil et al., 2014).  
   
 
To exit the dormant state, cells need external stimuli and the activation of cyclin 
dependent kinases (CDKs). The signals needed for dormant CSCs to start to 
proliferate are poorly understood. It is likely that the balance between stimulatory 
and inhibitory signals has to be disrupted to trigger proliferation. Like normal 
tissue SCs, it has been proposed that CSCs are located in specialized areas of the 
tumor microenvironment, called niches (Plaks et al., 2015) (Figure 3). Studies have 
shown that certain growth factors, for example transforming growth factor β (TGF-
β) (Salm et al., 2005) and hepatocyte growth factor (HGF) signaling (Nishida et al., 
2013) are important for prostate CSCs. Still, the niche of CSC in the prostate is 
poorly understood. CSCs are similar to tissue stem cells in that they are considered 
to be capable of symmetric and asymmetric divisions. The importance of Notch 
Figure 2. Tumor hetero-
geneity and CSCs.  
A, two models, stochastic 
and hierarchical, have 
been developed to explain 
the cellular heterogeneity 
of tumors. In the stochastic 
model all cancer cells are 
equal in their tumorigenic 
potential. In the hierarchical 
model CSCs are on top of 
hierarchy, being able to 
grow new tumors and 
cause heterogeneity by 
division generating progenitor  
cells, which further divide 
into differentiated cancer 
cells.  
B, CSCs may be dormant, 
resistant to chemotherapy 
and tumorigenic, which 
makes them the major 
reason for relapse. Targeting 
existing therapies for CSCs 
or directing CSCs to 
differentiate would create a 
novel type of therapy. 
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signaling has been indicated in colon CSCs (Bu et al., 2013) and distribution of 
CD133 between daughter cells determines the symmetric or asymmetric division 
(Lathia et al., 2011). Cell plasticity (epithelial to mesenchymal transition) and the 
microenvironment may also induce the de-differentiation of a malignant cell and 
this process provides another potential source for CSCs (Chaffer et al., 2011; Mani 
et al., 2008). CSCs should be considered as non-static populations of cells with a 
certain potential to contribute to cancer development (Shackleton et al., 2009). 
Eliminating CSCs or preventing the differentiation of CSCs could be a successful 
approach in many cancers. In addition, specifically targeting prostate CSCs by 
using cell surface marker proteins has been proposed as a novel therapeutic 
strategy. 
 
Figure 3.  Stem cells (SC) and cancer stem cells (CSC) are supported by the niche. The 
phenotype and both symmetric and asymmetric cell division could be regulated by 
the niche. All cells, both normal and cancerous, may be progenitors of CSCs 
through mutagenesis. 
2.4.1 Prostate cancer stem cells 
Prostate cancer stem cells (PCSCs) share many marker proteins with prostate tissue 
SCs. These include the cell surface proteins: CD44, α2β1 integrinHigh, CD133, 
and Trop2, which have been used alone and in combination. Other markers 
proposed for PCSCs are CD166, aldehyde dehydrogenase (ALDH) and the ATP‐
binding cassette sub‐family G member 2 (ABCG2), PSA, NANOG or “side 
populations” identified based on Hoechst dye staining (Skvortsov et al., 2018). 
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Methodologies, such as fluorescence-activated cell sorting (FACS) and magnetic 
cell sorting (MACS), have mainly contributed to the research into marker protein-
based CSC research. However, many shortcomings presist in CSC and their niche 
research, which can predominantly be attributed to technological challenges. The 
problem with using cell surface marker proteins to identify PCSCs is that these 
proteins are not exclusively expressed only by PCSCs, but also by normal tissue 
stem cells and on cancer cells of another type. Furthermore, the extensively used 
transplantation assays used to show long-term survival and the re-population of 
tissue have several problems (Plaks et al., 2015). 
2.5 Integrins 
Adhesion to the surrounding ECM is essential for many physiological processes, 
like embryonic development and tissue homeostasis, and often altered under 
pathological conditions, such as inflammation or tumor development. Integrins are 
a group of transmembrane adhesion receptors that consist of 18 α-subunits and 8 β-
subunits. Each subunit is a glycoprotein consisting of a large globular extracellular 
domain, transmembrane domain and usually a small intracellular tail. Humans have 
24 different functional integrin receptors, which are composed of one α and β 
subunit linked by non-covalent interactions. The heterodimers can be divided into 
subfamilies based on their ligands or on their phylogenic origin. The subfamilies 
comprise 1) collagen-binding integrins, 2) laminin-binding integrins, 3) RGD-motif 
binding integrins and 4) leukocyte specific integrins 5) a subgroup formed by α4 
and α9 integrins (Johnson et al., 2009). Based on the structure of the α-subunit 
head domain, integrins can be divided into 2 groups: integrins containing an αI-
domain and itegrins without it. Integrin αI-domain is also reffered to as the von 
Willebrand factor A-like domain or shortly as the αA domain based on the 
similarity. Integrins with an αI-domain bind to their ligands through the αI-domain 
whereas integrins which lack an αI-domain bind to their ligands using the interface 
of the βI-domain and the β-propeller domain in the α-subunit (Campbell and 
Humphries 2011). Although some integrins have only one known ligand (for 
example α6β4 binds to laminin), many integrins can bind to several ECM proteins 
(for example α2β1 binds to Collagen I, II, III, IV, V, VII, VIII, IX, X, XVI, XXIII, 
laminins, osteopontin and tenascin) (Heino 2007). The expression pattern of 
integrins on a cell surface and the selection of the ligands bound can determine the 
cell behavior in response to the surrounding microenvironment. As soon as the 
extracellular part of an integrin is bound to an ECM protein and the integrin tail is 
connected to the cytoskeleton the cells can obtain mechanical and chemical signals 
that regulate cellular responses, such as, growth, migration, differentiation and 
survival. 
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Ligand binding induces conformational changes in the receptor structure and 
consequently the intracellular parts of α and β units, also calles “legs” move apart 
from each other. Small cytoplasmic tails of integrin subunits are well conserved 
and crucial for regulating the activation of integrins (Calderwood 2004). The space 
created by the β-subunit conformational change between the tails of the α and β 
subunits enables various intracellular signaling proteins and cytoskeletal adaptor 
proteins to bind. The activation of integrins can happen either by binding the 
extracellular ligand and signaling outside-in or the integrin can be activated from 
the inside to bind the ligand on the outside of the cell (Campbell and Humphries 
2011). Once integrins are activated by ligand binding they can cluster to form focal 
adhesions. 
Integrin-based macromolecular complexes “bridge” ECM to the actin and 
through actin microfilaments connect it to a nuclear envelop. This is one of the 
mechanisms through which integrins mediate mechanical signals into cells. 
Integrins are also known to use chemical signals in cell regulation, for example, 
they activate focal adhesion kinase (FAK), tyrosinekinase Src and phosphoinositide 
3-kinase (PI3K) with their downstream signaling pathways. The mechanosensing 
and chemical signals mediated by integrins and focal adhesions also regulate the 
responses to the extracellular force and stiffness of the matrix. Cells continuously 
modify the extracellular mileu based on these signals. 
2.5.1 The collagen binding integrins 
The subfamily of collagen-binding integrins consists of four α-subunits: α1, α2, 
α10 and α11. All four have an αI-domain in their α-subunit and can only form 
heterodimers with β1-subunits. As the name collagen-binding indicates, the main 
ligands for all four receptors are members of the large collagen family. These 
receptors use their αI-domain to recognize distinct collagens with varying 
affinities, but all of them can specifically recognize GXX´GER-like motifs, such as 
GFOGER (single letter amino acid nomenclature, O = hydroxyproline) motif in 
collagen triple helices (Knight et al., 2000; Zhang et al., 2003). Integrins α1β1 and 
α2β1 are the main collagen receptors, whereas α10β1 and α11β1 were discovered 
later and knowledge about these integrins is updated continuously. While α2β1 is 
expressed on platelets, endothelial, epithelial, some mesenchymal and certain 
inflammatory cells, integrin α1β1is expressed on fibroblasts, smooth muscle cells, 
lymphocytes and chondrocytes. Integrin α10β1 is also expressed by chondrocytes 
(Camper, Hellman, and Lundgren-Åkerlund 1998). Integrin α11β1 is known to be 
expressed on mesenchymal stem cells (MSCs) (Tiger et al., 2001) and to be an 
important integrin for fibroblastic cells (Zeltz et al., 2014). Integrin α11β1 
expression on cancer associated fibroblasts regulates matrix stiffening in response 
to TGF-β (Carracedo et al., 2010). Recent studies support the role of integrin 
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α11β1 in several malignancies, including lung, breast and prostate cancer 
progression (Smeland et al., 2019; Reigstad et al., 2016; Navab et al., 2016). 
When comparing the similarity of collagen-binding integrin α-subunits, then α1 
and α2 are most closely related; α11 share the highest similarity to α10 (42%) and 
form a separate branch in the protein phylogenetic tree based on the alignment of 
the protein amino acid sequences (Velling et al., 1999). However, in ligand 
preferences α1β1 and α10β1 resemble each other and bind to BM collagen IV with 
higher affinity than they bind to fibril-forming collagens. In contrast, α2β1 and 
α11β1 tend to prefer binding to fibril-forming collagens (Tuckwell, et al., 1995; 
Tiger et al., 2001; Jokinen et al., 2004; Tulla et al., 2008; Lahti et al., 2011). 
Studies on knockout mice for all four collagen-binding integrin α-subunits have 
been published. Integrin α1 was the first for which a knockout was made. Mice 
without integrin α1 develop normally and are fertile. The isolated embryonic 
fibroblasts (EFs) fail to attach to type IV collagen and have decreased binding to 
laminin, but no defects in spreading on collagen I. The results from this study 
indicated that to a great extent, the attachment to type IV collagen is mediated by 
α1β1, but for binding to collagen I EFs might have another integrin in addition to 
α1β1 and α2β1 (Gardner et al., 1996). Next, knockout mice for integrin α2 were 
generated; these were also viable, fertile and seemed to develop normal. However, 
some abnormalities have been discovered, for example markedly reduced 
mammary gland development (J. Chen et al., 2002) and increased breast cancer 
metastasis which have been connected with the diminished expression of integrin 
α2β1 (Ramirez et al., 2011). Integrin α2β1 is expressed on platelets, so it has been 
assumed that the knockout of α2 integrin has a major role in hemostasis. However, 
platelets from α2 knockout show delayed, but not reduced attachment to collagen 
type I. This suggests that integrin α2β1 has a supportive, not essential role in 
normal homeostasis (Holtkötter et al., 2002). The mild cartilage defects found in 
α10β1 knockout mice were assumed, since chondrocytes primarily express this 
integrin in vivo (Bengtsson et al., 2005). More recently, the nonsense mutation in 
the ITGA10 gene was discovered to cause the diminished expression of integrin 
α10β1 resulting in chondrodysplasia in dogs (Kyöstilä et al., 2013). Integrin α11β1 
knockout mice are viable but display dwarfism with increased mortality (Popova et 
al., 2007). Integrin α11β1 is expressed mainly on MSCs and on a subset of 
fibroblasts. TGF-β binding to its receptor induces Acta2 (which encodes αSMA), 
connected with myofibroblast differentiation and also up-regulates α11β1 integrin, 
which is needed to stabilize α-SMA protein expression (Carracedo et al., 2010). In 
addition, integrin α11β1 participates in collagen reorganization, which explains the 
wound healing defects indicated in α11β1 knockout mice (Schulz et al., 2015). 
Thus, collagen-binding integrins have no functions that are critical for normal 
homeostasis; however in conditions such as inflammation, wound healing and 
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tumorigenesis collagen-binding integrins may play a more crucial role (Zeltz and 
Gullberg 2016). 
2.5.2 Integrin α2β1 mediated signaling 
Although integrin α2β1 does not have kinase activity, it is able to activate several 
kinases, for example, FAK, Akt/protein kinase B, PI3K (Holtkötter et al., 2002) 
and protein 38 mitogen-activated protein kinase (p38 MAPK) (Ivaska, et al., 1999). 
In addition, integrin α2β1 also activates protein serine/threonine phosphatase 2A 
(PPA2), p27KIP1 and the Rho family GTPases (Ivaska et al., 2002; Henriet et al., 
2000). The following shortly explains how integrins activate kinases and their 
importance on cell regulation.  
FAK is an intracellular non-receptor tyrosine kinase, which associates with 
receptors at the plasma membrane. The classical mechanism of FAK activation is 
initiated by integrin clustering and the formation of focal adhesion complex after 
cells have bound to the ECM (Mitra and Schlaepfer 2006). The activation of FAK 
requires its dimerization and auto-phosphorylation at Y397 (Brami-Cherrier et al., 
2014). FAK phosphorylation at Y397 allows Src-kinase and PI3K to bind through 
the SH2-domain. Further phosphorylation of the FAK residues 576 and 577 is 
induced by Src to create more binding sites and trigger downstream signaling. 
Other proteins which can bind to FAK are paxillin, talin vinculin, Grb2, p130Cas, 
and Shc, which become activated through interaction with FAK and participate in 
the regulation of cell migration and proliferation. Besides the important role of 
FAK as a kinase, it also has crucial scaffolding properties. FAK-mediated cell 
cycle regulation and responses to stress take place through its interactions with p53 
and MDM2 (Golubovskaya et al., 2008, 2013). FAK can activate the Akt pathway, 
but β1 integrins also directly induce the phosphorylation of Akt at Ser473 and 
Thr308 in a PI3K-dependent manner (Velling et al., 2004). 
The MAPK pathway connects integrin α2β1 to the regulation of the cell cycle. 
As such, the balance between the stress-regulated p38 pathway and mitogen 
activated ERK signaling can regulate cell cycle progression and switch from 
dormancy to active proliferation (Aguirre-Ghiso et al., 2001). Recently it was 
shown that one specific subtype of p38 MAPK, namely gamma (p38γ), could act as 
a CDK-like kinase and cooperate with CDKs to regulate entry into the cell cycle 
(Tomás-Loba et al., 2019).  
Integrins crosstalk with many growth factor receptors (GFRs). Well-
characterized examples are the epidermal growth factor (EGF), the vasculature 
endothelial growth factor (VEGF), the insulin-like growth factor (IGF), and the 
hepatocyte growth factor receptor (HGFR / c-Met) (Ivaska and Heino 2011). 
Several types of crosstalk exist. Integrins have shown to directly bind to GFRs, and 
as well as having the potential to activate GFRs even when the GF itself is not 
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present, integrins can also amplify GFR-induced signals through binding to the 
ECM proteins and activating the same signaling pathway in addition to GFRs. An 
example of such crosstalk is the interplay between TGF-βR and integrin α2β1, in 
which integrin-collagen interaction changes growth factor signaling (Garamszegi et 
al., 2010). In addition, many GFs can also induce the expression of the integrins 
and in this way regulate cell-ECM signaling. HGF signaling through its receptor c-
Met is known to induce integrin α2 expression (Chiu et al., 2002) and the 
interaction between integrin α2β1 with c-Met regulates innate immunity (Mccall-
Culbreath et al., 2008). Anchorage independent growth can also be induced by 
interaction between α2β1 integrin with c-Met to facilitate tumorigenesis (Barrow-
McGee et al., 2016). Intergins also crosstalk with non-classical GFRs, for example 
the Eph receptor. Ephrin signaling induces the adhesion of PC3 cells on collagen 
type I through β1 integrin (Yu et al., 2015).  
The signals induced by GFR and integrins can be GF and matrix protein 
specific. Although the binding of integrin α5β1 to fibronectin results in cell cycle 
progression, when integrin α2β1 binds to the laminin in the same cells, it induces 
growth arrest (Mettouchi et al., 2001).  
In normal cells, integrins mediate strong survival signals and the GF-induced 
signal can remain hidden. Once integrin signals are removed cells undergo growth 
arrest and anoikis because of the impaired signals from GFs and cytokines (Danen 
and Yamada 2001). To avoid anoikis, the necessary signals include the interaction 
of the integrins with ECM proteins, the activation of FAK and the downstream 
signaling of the PI3K-Akt pathway (Frisch and Ruoslahti 1997). Recent studies 
have shown that integrins can also activate FAK in endosomes to help cells avoid 
anoikis (Alanko et al., 2015). Studies into tumor cells have opened up the signaling 
to avoid anoikis. In contrast to normal cells, a population of invasive cancer cells is 
resistant to anoikis. For these cancer cells detachment from the ECM and 
neighboring cells does not induce cell death, while the cell leaves the primary site 
and travels through the lymphatic or vasculature vessels to a distant site. Metastatic 
malignant cells have developed numerous ways to escape from anoikis, a hallmark 
of metastatic malignancy. These mechanisms are somewhat similar to those seen in 
drug resistance and include the upregulation of kinases (Douma et al., 2004) and 
scaffolding molecules (Parsons et al., 2009), the suppression of apoptotic pathways 
(Simpson, Anyiwe, and Schimmer 2008), and the downregulation of critical 
anoikis regulators seen in normal epithelial cells (Rohwer et al., 2008). 
Furthermore, cells that are able to survive anoikis, have been shown to be harder to 
target due to the decreased levels of p53 in the cells detached from the ECM 
(Truong et al., 2003). 
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2.5.3 Regulation of α2β1 integrin in prostate cancer 
The fact that bone matrix is composed of various collagens makes it one of the 
main metastatic locations in prostate cancer. Integrin α2β1, the main cellular 
receptor for collagens, is very attractive as a target for disseminating prostate 
cancer. However, published data about the expression of integrin α2 during 
prostate cancer development is controversial. 
Firstly, Bonkhoff and colleagues indicated that α2 integrin expression is 
downregulated in Grade I and II PC; in Grade III integrin expression was shown to 
be highly heterogeneous while corresponding lymph node metastasis had an 
increased expression of integrin α2 (Bonkhoff et al., 1993). Our group has also 
shown that integrin α2β1 expression at an mRNA level decreases during cancer 
progression, being lowest in high-grade carcinomas. At protein level, the same 
effect was shown, the strongest α2 staining was seen in luminal epithelial cells and 
staining decreased in PIN and further in parallel with poor differentiation of the 
prostate carcinomas (Mirtti et al., 2006). The possible differential expression of α2 
integrin could be obtained by epigenetic regulation (Chin et al., 2015). Lymph 
node metastasis of prostate cancer also has controversial findings. A noticeable 
expression of integrin α2β1 in disseminated cancer cells was reported by (Bonkhoff 
et al., 1993). Conversely, prostate cancer lymph node metastasis have been 
indicated to have low integrin α2β1 expression levels (Pontes-Junior et al., 2009) in 
another study. Functionally the role of integrin α2β1 could be tissue specific as 
studies have confirmed that prostate cancer cells that are able to initiate micro-
metastasis have to have integrin α2β1 expression (Kostenuik et al., 1996; Sottnik et 
al., 2013). However, in breast cancer the integrin α2β1 has been proposed to have a 
metastasis-suppressor role (Ramirez et al., 2011). 
2.5.4 α2β1 integrin in prostate cancer stem cells 
Several studies have indicated that integrin α2β1 is essential in prostate cancer 
dissemination. The information that integrin α2 expression is downregulated in 
prostate tumors does not exclude the possibility that a high expression in a subset 
of tumor cells, especially CSCs, is important for metastatic behavior, especially in 
collagen I rich bone microenvironment. 
2.6 Tumor microenvironment 
Cancer cells are not isolated from the surrounding tissue, called tumor stroma or 
the tumor microenvironment (TME). The TME is continuously evolving together 
with oncogenic signals from malignant cells and with the normal cells present in 
the area of malignant growth. One cannot underestimate the role of TME in 
Marjaana Ojalill 
 26 
metastasis formation from the very first transformed cell division. Cancer cells 
secrete cytokines and chemokines to support their own growth in an autocrine 
manner. They activate nearby stromal cells, recruit immune cells and trigger 
angiogenesis. These events alter the normal homeostasis of the tissue and modify 
the TME. The TME is a niche for cancer cells to proliferate and to create local or 
distant metastasis. Figure 4 depicts the TME with all the included cell types. The 
contribution of these cells and processes regulating cancer growth and spreading 
have been covered in numerous reviews (Hanahan and Weinberg, 2011; Balkwill et 
al., 2012). 
 
Figure 4.  Tumor microenvironment. Several sub-populations of malignant cells can be found 
in tumors. Cancer cells (pink), cancer cells from hypoxic or necrotic areas (brown) 
and cancer stem-like cells (not shown). Stromal cells as cancer associated 
fibroblasts (CAFs) (light yellow) and mesenchymal stem cells (dark yellow). The 
lymphatic and neovasculature system consisting of endothelial cells (dark pink), 
lymphatic endothelial cells (light green), pericytes (orange) and blood cells (red). 
Immune system cells: natural killer (NK) cells (darker orange), macrophages 
(darker green), dendritic cells (light blue) and T- (purple) and B-lymphocytes (dark 
blue). Non-cellular part as extracelluar matrix (ECM) (gray waves). Figure modified 
with permission from Balkwill et al., 2012. 
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2.6.1 Fibroblasts  
Fibroblasts are a population of elongated, spindle-shaped cells typically located in 
the stroma. They are considered to be of mesenchymal origin and they share 
similarities with smooth muscle cells. Since there are no specific markers for a 
fibroblast, this cell type is recognized based on shape, the co-expression of 
mesenchymal and smooth muscle markers and the absence of a marker for other 
cell types. The most common markers used to identify fibroblasts are α-smooth 
muscle actin (α-SMA), desmin, fibroblast specific marker 1 (FSP1) and α1β1 
integrin (Kalluri and Zeisberg 2006). Fibroblasts are remarkably activated during 
embryonic development, when all the matrices in tissues are produced. Later, they 
are quiescent in normal adult tissues and activated in cases of inflammation, wound 
healing or tumorigenic growth (Kalluri 2016). The deposition of the ECM is one 
mechanism for fibroblasts to help them to maintain the homeostasis of tissues. The 
ECM produced by stromal fibroblasts regulates the phenotype and behavior of 
epithelial cells and modifies inflammation. Fibroblasts can be isolated from various 
tissues and cultured. In cell culture studies, fibroblasts are frequently used but they 
become immediately activated in cell culture conditions (Attieh and Vignjevic 
2016). Quiescent fibroblasts have the ability to respond to growth factors and 
become activated. This leads to proliferation, migration, the production of growth 
factors and the active synthesis/remodeling of the ECM. Fibroblasts from distant 
tissues exhibit distinct and characteristic gene expression patterns and should be 
considered individual cell lines, although activation is occurring, some original 
properties remain even in vitro (Chang et al., 2002). 
2.6.2 Activated fibroblasts 
Fibroblasts are activated as a consequence of altered gene expression in cancer 
cells. Cytokines and growth factors mediate the effects of malignant cells 
(Kalluri and Zeisberg 2006). Activated fibroblasts, also called myofibroblasts, or 
in the context of cancer peritumoral fibroblasts, reactive stromal fibroblasts, 
cancer associated fibroblasts (CAFs) or tumor associated fibroblasts, are highly 
heterogeneous and may originate from different cell types (Micallef et al., 2012; 
Kalluri 2016). Activated fibroblasts were first detected during wound healing 
based on their expression of α-SMA (Micallef et al., 2012). α-SMA is so far the 
most prominent marker used to detect activated fibroblasts. Once fibroblastic 
cells are activated, their phenotype changes, for example, the nucleus is usually 
enlarged, the ER and Golgi become more apparent and protein synthesis is 
activated (Kalluri and Zeisberg 2006). In contrast to non-activated fibroblasts, 
which are mostly quiescent or in slow-cycle self-renewal, myofibroblasts actively 
proliferate. 
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For a long time, it was thought that the activated phenotype of fibroblasts is 
only a consequence of tumor growth. However, it is now known that CAFs actively 
participate in the progression of cancer. CAFs, immune cells and cancer cells 
collectively contribute to the formation of a cancer specific ECM and in tumor 
growth. In many cancer types, the altered, stiffer and directional organization of the 
ECM has been shown to facilitate cancer cell invasion (Attieh et al., 2017). In the 
prostate, fibroblasts become activated even in the precancerous PIN state (Tuxhorn 
et al., 2002). 
2.6.3 ECM 
The ECM is the non-cellular component of the tissue microenvironment. 
Consisting of a variety of matrix proteins, the ECM provides a scaffold for cells 
and integrity for tissues. The exact composition and structure of the ECM varies in 
different tissues and depends on certain processes, such as development, wound 
healing, tumor growth or ageing. The ECM provides more than just a scaffold, it 
has a far more complex role, since it is crucial for stem cell niches and in 
development. Alterations of the ECM in cancer development has received 
considerable attention (Richard O Hynes 2009).  
The ECM can be divided into loose connective tissue and the more specialized 
matrix “basal lamina”. Basal lamina or BM is a thin (40-120 nm) flexible sheet of 
well interconnected proteins that separates epithelial structures from connective 
tissue. In addition to its separation function, BM also determines cell polarity and 
regulates cell survival, proliferation and differentiation. Although the basal laminas 
in different tissues may have a slightly distinct composition, the typical 
components of the BM include collagen IV, laminins, nidogen 1and 2, perlecan, 
agrin and collagen XV and XVIII (Theocharis et al., 2016). The BM is synthesized 
co-operatively by cells on both sides of the membrane, the laminin network being 
on the epithelial side and collagen IV network localizing on the stromal side. 
Epithelial cells bind to the BM and connect it to the intracellular intermediate 
filaments using integrin-mediated attachment structures - hemidesmosomes. 
Hemidesmosomes are responsible for anchoring the epithelial cell layers to the 
BM, regulating cell polarity and have tumor suppressive function (De Arcangelis et 
al., 2017). 
The connective tissue ECM is synthesized by the cells resident in the matrix. In 
many tissues these cells are fibroblasts, in specialized tissues other mesenchymal 
cells produce the matrix, for example, in bone these cells are osteoblasts. The 
typical loose connective tissue ECM is composed of collagens, which together with 
fibronectin provide the mechanical strength of the tissue and from proteoglycans, 
which provide the GF and cytokine binding sites and interconnections of ECM 
proteins (Erler and Weaver 2009).  
Review of the Literature 
 29 
Each organ of the human body under normal conditions has optimal, well-
regulated tissue stiffness. During cancer development, however, the ECM changes, 
for example its stiffness, because of the excessive synthesis of ECM components 
and the remodeling of the ECM structure by proteolytic enzymes. A good example 
of tissue stiffness due to increased ECM and CAFs is breast cancer, which can be 
discovered because of the presence of a lump in the breast. This lump might reflect 
the tumorigenic growth of cancer cells, an increased number of CAFs and the 
accumulated connective tissue around it, called desmoplasia. Desmoplasia is an 
extra fibrous matrix synthesized and remodeled by CAFs. The increased number of 
CAFs and ECM in invasive ductal carcinoma is called fibrotic foci, which is 
connected with a more aggressive disease and metastatic potential (Hasebe et al., 
2001). 
2.6.3.1 Proteoglycans 
Proteoglycans (PG) are proteins which have linked glycosaminoglycan (GAG) 
chains. Large GAG chains fill the extracellular space and help to form a porous 
hydrated gel-like structure, which is resistant to compressive forces. Hyaluronan 
(HA) is a linear GAG, it is synthesized on the cell surface. HA can be either protein 
-free or as non-covalently attached to other PGs. HA polymers can be various sizes 
and act as signaling molecules. HA is produced by hyaluronan synthases (HAS) 
and the degradation of HA is performed by hyaluronidases (HYALs), which can 
degrade HA into low molecular weight fragments (Theocharis et al., 2016). 
Proteoglycans can be classified into four families: extracellular, intracellular, BM 
and cell-surface ones. Extracellular PGs can be divided again into 2 sub-families. 
First, HA- and lectin-binding PGs (hyalectans), from which the most common 
proteins are aggrecan and versican, and secondly, small leucine-rich PGs (SLRPs). 
Decorin, biglycan and lumican are some examples of SLRPs, which can participate 
in several biological processes. SLRPs can interact with collagens and participate 
in collagen fibrillogenesis and by binding to RTKs they can modulate cell signaling 
pathways (Iozzo and Schaefer 2015). The BM PG family consists of perlecan, 
agrin and collagen XV and XVIII, all of which participate in the BM organization. 
Perlecan and agrin share a structurally organized C-terminus, endorepellin, which 
can be cleaved by metalloproteinases (MMPs). Collagen XV and XVIII also share 
some structural properties and be cleaved by MMPs and other proteinases. Cell 
surface PGs, as the name indicates, are attached to cell membranes. Syndecans and 
glypicans are the two main sub-families. Syndecans can interact with fibronectin, 
laminins and collagens. Syndecan-1 is a co-receptor for collagen with integrin 
α2β1 and known to induce the transcription of MMP1 (Vuoriluoto et al., 2008). 
Glypicans are a family which consists of six glycosylphosphatidylinositol (GPI)-
anchored members, glypican 1-6. Glypicans can bind and modulate several GFs, 
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for example Wnt signaling (Theocharis et al., 2016). In addition to their structural 
role, most proteoglycans are able to modulate the signaling between the cells via 
regulating the availability of growth factors.  
2.6.3.2 Collagens 
Collagens are abundant and constitute up to 30% of the total human proteins. The 
collagen superfamily consists of 28 different collagen types, which are expressed 
through the body. Collagen I is a major structural element for tissues such as bone, 
dermis and tendon (Heino 2007). Collagens differ from each other in their 
structure, properties and the tissues where they are expressed. Collagens can be 
classified into seven categories as fibrillar collagens, network-forming collagens, 
FACITs (fibril-assiciated collagens with interupted triple helices), MACITs 
(membrane-associated collagens with interupted triple helices), anchoring fibrils, 
beaded-filament-forming collagens, and MULTIPLEXIN (multiple triple-helix 
domains and interruptions) (Theocharis et al., 2016). 
2.6.3.3 Glycoproteins 
The fiber-forming protein fibronectin (FN) is expressed by several cell types. FN is 
encoded by a single gene, but due to alternative splicing, the 20 distinct proteins 
exist in humans. FN can either be soluble plasma FN or cellular FN, which is 
assembled into fibers. In vitro cells are able to produce their own FN, secrete it and 
then assemble it. FN consists of two covalently linked subunits (250 kDa), which 
contain three types of repeating modules. FN contains 12 type I repeats, two type II 
repeats and 15-17 type III repeats. The FN protein has fibrin-, collagen/gelatin and 
fibrillin binding sites. It can interact with proangiogenic factors VEGF and HGF 
(R.O. Hynes et al., 2002). The main integrin-binding site RGD and second 
integrin-binding LDV are used by cells to bind to FN (Richard O Hynes 2009).  
Another group of glycoproteins are laminins. These proteins consist of one α, 
one β and one γ subunit, each of which are transcribed from an individual gene. It 
is known that there are 5 α genes (LAMA1-5), 3 β genes (LAMB1-3) and 3 γ genes 
(LAMC1-3) and LAMA3 has 2 isoforms, long and short, which gives six possible α 
genes although there would be possibly 51 potential trimers, only sixteen have 
been found in human (Durbeej 2010). According to the newer nomenclature the 
names of laminins are based on the heterotrimers formed, for example α1, β1 and 
γ1 form laminin-111 (Aumailley et al., 2005). Laminins bind each other as well as 
other ECM proteins. Binding sites for nidogens, fibulins, perlecan, heparin, 
sulfatides and agrin are known. The main cellular receptors for laminins are 
integrins and syndecans. Laminins are crucial for embryonic development and 
organogenesis (Durbeej 2010).  
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2.6.3.4 Matricellular proteins 
The ECM also contains proteins, which do not have a structural role, but contribute 
to the integrity of the ECM by modulating the cell-cell and cell-ECM interactions. 
These proteins have been categorized as matricellular. They interact with the 
structural ECM proteins, bind to a large variety of receptors on the cell surface and 
regulate the cell-matrix interactions (Bornstein and Sage 2002). The matricellular 
proteins group includes CCN proteins, galectins, thrombospondin 1 and 2, SPARC 
(secreted protein, acidic and rich in cysteine; also known as osteonectin), the 
SIBLING family (small integrin-binding ligand N-linked glycoproteins), periostin 
(POSTN), TINAGL, tenascin C and X (Bornstein and Sage 2002; Li et al., 2007; 
Thakur and Mishra 2016). Matricellular proteins in adult tissues show diminished 
to moderate expression levels. However, in developing tissues, and pathological 
conditions such as tumor growth, their expression increases notably (Wong and 
Rustgi 2013).  
2.6.4 Proteolytic regulation of ECM composition. 
The proteolytic turnover of the ECM is required for normal physiological processes 
like development and wound healing, as well as in tumor growth and metastasis. 
Based on their catalytic activity and cofactor requirements, enzymes degrading 
ECM can be divided into four groups: aspartic, cysteine and serine proteinases, 
metalloproteinases (MMPs). MMPs are a family of zinc-dependent endopeptidases 
which can regulate ECM composition, since they can degrade collagens, matrix 
glycoproteins, and proteoglycans, and ECM properties by regulating growth factors 
and their receptors, as well as cytokines and chemokines in ECM (Sternlicht and 
Werb 2001). MMPs have been associated with tumor progression and cancer cell 
invasion (Gialeli, Theocharis, and Karamanos 2011). MMPs can be divided into 
several subgroups, which have been thoroughly reviewed (Reunanen and Kähäri 
2002). In the context of this work, the most interesting subgroups are collagenases 
and transmembrane MMPs. The group of collagenases contains three members 
MMP1, MMP8 and MMP13. These major proteinases can cleave fibrillar 
collagens. MMP1 can degrade several components of the ECM, including collagen 
types I, II, III, VII, VIII and X, aggrecan, fibronectin, perlecan and tenascin 
(Sternlicht and Werb 2001). MMP1 has been shown to be crucial for prostate 
cancer DU145 cells to invade (Yoneda et al., 2010) and its synergy with integrin 
α2β1 has also been reported (Dumin et al., 2001; Riikonen et al., 1995).  
Membrane type MMP1 (MT-MMP1/ MMP14) belongs to the membrane-
bound MMP subfamily. In addition to many other cancer types, MMP14 is found 
in prostate carcinoma, where it is expressed either by cancer cells or CAFs. 
Macrophages and endothelial cells have been shown to express MMP14 as well 
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(Rowe and Weiss 2009). MMP14 has many substrates, including fibronectin, 
collagen type I, tenascin and laminin-332 (Sternlicht and Werb 2001).  
Four endogenous protease inhibitors form the family of Tissue inhibitors of 
metalloproteinases (TIMPs). Classically, TIMPs inhibit the MMP-mediated 
degradation of ECM and additionally have other roles in regulating apoptosis and 
angiogenesis. TIMP1 has been the most intensively investigated TIMP. In 
colorectal cancer, TIMP1 is exclusively expressed by CAFs at the invasive front of 
the tumor (Holten-Andersen et al., 2005). Whereas, in prostate cancer TIMP-1 is 
expressed by both CAFs and prostate cancer cells (Gong et al., 2013). These results 
suggest that TIMP-1 expression and role might be tumor type specific. 
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3 Aims of the Study 
The aims for this thesis were set in agreement with the Marie Curie Initial Training 
Network CAFFEIN. The goal was to increase knowledge about the function of 
cancer associated fibroblasts in tumor expansion and invasion. Based on this, the 
specific aims were: 
1. To study the composition of the human prostate extracellular matrix (ECM) 
by mass spectrometry and proteomics. 
2. To isolate human prostate-derived fibroblast cell lines in order to study their 
ECM in in vitro 2D and 3D systems and to compare it to the in vivo 
produced ECM. 
3. To study the role of integrin α2β1 in DU145 prostate cancer cells by creating 
an α2 knockout with Crispr/Cas9 and to perform functional studies on 
invasion, proliferation and gene expression. 
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4 Materials and Methods 
The extensively used materials and methods applied in this thesis work are listed 
here and have been described in detail in the original publications. The specific 
methods used for this study have been explained in detail below. 
Table 1.  Methods 
Method Used in 
Flow cytometry I 
Flow assisted cell sorting I 
Confocal microscopy I-III 
Live microscopy II, III 
Mass spectrometry and proteomics II,III 
Western Blot I,III 
Real time cell adhesion measurement with xCelligence system III 
Out from spheroid migration and invasion assay I,III 
RT-qPCR I,II 
Matrigel transwell invasion assay I  
Cell proliferation analysis I, II 
Cell cycle analysis I 
Colony survival assay I 
Extraction of ECM proteins from human prostate tissue II 
Immunohistochemistry III 
3D spheroid culture system I-III 
RNA sequencing I 
Immunocytochemistry I-III 
Image analysis I-III 
4.1 Human prostate tissue samples 
In order to study the in vivo composition of the human prostate ECM the matrix 
proteins were extracted from 12 human prostates tissue samples, from 6 cancerous 
and 6 non-cancerous locations. In addition, prostate tissue samples were used to 
isolate human primary cells to initiate fibroblast cell lines (27 cell lines were 
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created during the study). The tissue samples were obtained from surgically 
removed prostates using robotic-assisted laparoscopic prostatectomy (RALP) at the 
Turku University Hospital during 2013-2014. All patients signed the informed 
consent to allow the use of their tissue material for scientific research conducted by 
the Turku Prostate Cancer Consortium Study (TPCCS). This study has been 
approved by the ethics committee of the Hospital District of Southwest Finland 
(ETMK: 3/180/2013). 
4.2 Cell cultures 
Human androgen independent prostate cancer cell lines DU145 and PC3 were 
purchased from the American Type Culture Collection (ATCC). DU145 cells The 
origin of DU145 cells are prostate cancer metastasizing to brain and PC3 cells from 
a metastatic bone lesion. Human prostate-derived fibroblastic cultures were 
developed in-house according to the published protocol (Le et al., 2006). All cells 
were cultivated in RPMI 1640 medium, supplemented with 2mM ultraglutamine, 
10% fetal calf serum (FCS), 100U/ml penicillin and streptomycin. For serum-free 
conditions the FCS was omitted and serum-free keratinocyte medium (KSF) with 5 
ng/ml human recombinant EGF, 50 μg/ml bovine pituitary extract, supplemented 
with 2 ng/ml recombinant human leukemia inhibitory factor and 2 ng/ml stem cell 
factor (Sigma Aldrich) was used in indicated experiments. Cells were routinely 
screened with the MycoAlert™ PLUS mycoplasma detection kit. 
4.3 Genome editing for knock-out and rescue of α2 
integrin 
To create integrin α2 negative DU145 cells Crispr/ Cas9 genome editing was 
applied. A commercial all-in-one vector (Sigma, HS0000253951 gRNA sequence: 
GTTACTGGTTGGTTCACCCTGG) was transfected into the DU145 cells. A 
transient transfection was confirmed and a positive population of transfected cells 
was sorted based on their expression of GFP. The GFP expressing cells represented 
a mixed population of ITGA2 knockout and α2 integrin positive cells. Therefore, 
the cells were stained against α2 integrin, the negative population was identified 
and sorted separatly. These cells were labelled as DU145KO. To create cells with 
rescued integrin α2 expression ( called DU145KO+α2 cells), DU145KO cells were 
stably transfected with the pAWneo2 vector carrying α2 integrin cDNA (Ivaska, et 
al., 1999) or with the empty pAWneo2 vector to create a proper α2 negative control 
cell line (DU145KO+vector). To ensure the stable expression of the vector 
constructs the cells were cultured in the presence of 250 µg/ml of G418. 
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4.4 Gene expression analysis 
Table 2.  Primers and probes used for qPCR 
Gene Forward primer Reverse primer Probe 
CHD5 tgggctacatggatgagaaa ctcactctccactctatccaagg 11 
CDH5 aagcctctgattggcacagt gactcggaagaactggccc 58 
KIF26B cgtgttcttcacactgcacat ctgcgacctccagacattc 58 
LGI1 tcactaaccaaactgacattcctaa acacgtcccctttcactgag 88 
PKP1 aaacaggcacgtctggca aagccatcatacatggaacctc 68 
RBP1 acgctgagcacttttaggaact atgcctgtcagatcctcctc 12 
SCARA5 tccaagctgaacctgtgtga agaatcaggaagaccagcag 56 
SDC2 aaacggacagaagtcctagcag ccttcatccttctttctcatgc 18 
SVEP1 tctctgttggtttgcccata atggagcccacaaaagactc 26 
SYK aaagacaaatggaaagttcctga ctttgtcgatgcgatagtgc 40 
VWA2 gggtttgcagaggttgactg ctgcggtaccaccaggac 76 
MMP1 aagatgaaacgtggaccaacaatt ccaagagaatggaagagttc * 
ACTA2 cctatccccgggactaagac aggcagtgctgtcctcttct 78 
FAP tggcgatgaacaatatcctaga atccgaacaacgggattctt 19 
COL1A1 gggattccctggacctaaag ggaacacctcgctctcca 67 
COL3A1 ctggaccccagggtcttc gaccatctgatccagggtttc 20 
KRT8 tcaacaacaagtttgcctcct atgttgtccatgttgcttcg 1 
KRT 18 ggaagatggcgaggacttta atggtttgcatggagttgct 9 
POSTN aatgccaacagttactatgac cttgataccagttcttacagg 9 
GAPDH acccactcctccacctttga ttgctgtagccaaattcgttgt ** 
* 5’-FAM-cagagagtacaacttacatcgtgttgcggctc-TAMRA-3’ 
** 5’-FAM-acgaccactttgtcaagctcatttcctggt-TAMRA-3’ 
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4.5 Immunoassays 
Table 3.  List of antibodies used in this study 
Target protein Product code Company Method Used 
in 
Integrin α2 12F1, 
BD5555668 
BD Pharmingen FC, FACS I 
Integrin α2 Mab12332 R&D Systems IF I 
CD44-FITC Ab19622 Abcam FC, FACS I 
β-actin A1978 Merck WB I, III 
Hsp90 4877S Cell Signaling Technology WB I 
p38 MAPK, 
pT180/Y182 
9215L Cell Signaling Technology WB I 
FAK pY397 3283S Cell Signaling Technology WB I 
ERK 1/2, pT204/pT187 5726S Cell Signaling Technology WB I 
CREB, pS133 MAB6906 BD Biosciences WB I 
FAK 610088 BD Biosciences WB I 
ERK 9102S Cell Signaling Technology WB I 
Trop2 MAB650 BD Biosciences FC I 
αSMA ab32575 Abcam IF II 
Pan-cytokeratin 
(1,4,5,6,8,10,18,19) 
C2562 Merck IF II 
Collagen I ab6308 Abcam IF II 
Fibronectin ab6328 Abcam IF II 
Laminin5 ab14509 Abcam WB III 
Endostatin PA1-601 Thermo Fisher Scientific WB III 
MMP14 AB6004 Merck WB III 
Collagen XVIII N2, Ref homemade WB III 
WB: Western blot, IF: Immunofluorescence, FC: Flow cytometry, FACS: Fluorescence-activated 
cell sorting 
4.6 Reagents 
Table 4.  List of ECM proteins used in this study 
Protein Company, product code Used in 
Collagen I (Bovine) Advanced BioMatrix, 5010-50 I-III 
Fibronectin Merck, F1141 I-III 
Recombinant Human Endostatin Peprotech, 150-01 III 
Laminin-332 Biolamina III 
Poly-l-lysine Merck, P9155 I 
Marjaana Ojalill 
 38 
Table 5.  List of reagents used in the original publications. 
Regent Type Company, product 
code 
Used in 
Fugene 6 Transfection regent Promega I 
CellTracker™ Orange CMRA 
Dye 
Fluorescent stain Thermo Fisher Scientific, 
C34551 
II-III 
CellTracker™ Green CMFDA 
Dye 
Fluorescent stain Thermo Fisher Scientific, 
C7025 
II-III 
N-Isobutyl-N-(4-
methoxyphenylsulfonyl)-
glycylhydroxamic Acid, NNGH 
MMP inhibitor Merck I, III 
N-(benzyloxycarbonyl)-L-
phenylalanyl-L-tyrosinal, Z-FY-
CHO 
Cathepsin L inhibitor Santa Cruz 
Biotechnology 
III 
3,4-Dichloro-N-(1-methylbutyl)-
benzamide, 3,4-Dichloro-N-
(pentan-2-yl)benzamide, NSC 
405020 
MT1-MMP inhibitor Merck III 
NucleoSpin® RNA  RNA extraction kit Macherey-Nagel I 
4-(4-Fluorophenyl)-2-(4-
methylsulfinylphenyl)-5-(4-
pyridyl)-1H-imidazole, SB 
203580 
p38 MAPK inhibitor Merck I 
SensiFAST™ cDNA Synthesis 
Kit 
cDNA synthesis kit Bioline I, II 
ABI TaqMan 
Universal Master Mix II 
PCR mastermix Applied Biosystems I, II 
4.7 Data and statistical analysis 
Statistical analyses were performed using IBM SPSS statistics 22 software. The 
normal distribution of data was checked with Shapiro-Wilk test. A paired Student’s 
t-test was used to determine the statistical significance between the two treatments. 
Several treatment samples were compared with a one way ANOVA test and 
pairwise comparisons were made with the Tukey HSD and Dunnett T3 post hoc 
test. The statistical significance was considered for p-values less than 0.05. 
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5 Results 
5.1 Integrin α2, CD44 and Trop2 expression on 
DU145 and PC3 cells (I) 
The DU145 and PC3 cell lines were used as a model system for the cancer stem 
cells in this study. The expression of the stem cell markers α2 integrin, CD44 and 
Trop2 was studied using flow cytometry.The analysis of the markers expressed on 
the cells surfaces for both cell lines are shown in Figure 5. 
 
Figure 5.  PCSC markers: α2 integrin, CD44 and Trop2 expression levels on the DU145 and 
PC3 cell surface were determined by flow cytometry using human CD49b, CD44 
and Trop2 antibodies. Both, DU145 and PC3 cells express all three marker 
proteins on cells surface. The 5 * 104 cells were analyzed using BD 
LSRFortessa™ cell analyzer, data were analyzed with FlowJo v10 software. 
Marjaana Ojalill 
 40 
5.2 Docetaxel resistant cells show high prostate 
cancer stem cell marker expression (I) 
We first studied whether ECM or certain ECM proteins have protective properties 
for DU145 and PC3 cancer cells. The cancer cells were plated on the human 
prostate primary fibroblast-derived ECM or surface coated with the matrix proteins 
fibronectin or collagen I, and treated with docetaxel. Based on these data from our 
group, the ECM in 2D cell culture system does not have a protective role for cancer 
cells (Elina Aalto, Master’s thesis 2015). Next, we studied the cells which survived 
the docetaxel treatment. We discovered that the stem cell markers α2 integrin and 
the CD44 cell surface levels were higher on the DU145 cells treated with docetaxel 
than on the corresponding untreated cells (I, Figure 1A-B). The same effect of 
increased integrin α2 was seen with PC3 cells (I, Supplementary Figure 3A-B). As 
anticipated, the surviving cells were mostly arrested at the G2/M of the cell cycle 
(I, Supplementary Figure1).  
To study the α2 integrin high and low sub-populations, the DU145 and PC3 
cells were sorted using fluorescence-activated cells sorting (FACS) (I, Figure 1C). 
The sorted cells kept the expression profile for 5-7 passages. The levels of α2 
integrin, CD44 and Trop2 were studied at the 5th passage after sorting. The 
DU145WTα2High cells also expressed more CD44 than the DU145WTα2Low 
cells, suggesting that these stem cell markers are connected. There was no 
difference in the Trop2 expression on the DU145WTα2High and the 
DU145WTα2Low cells (I, Figure 1D). Surprisingly, the PC3 cells with a high 
expression of α2 integrin had lower levels of CD44 when compared to the 
PC3α2Low cells. Another interesting observation was that the PC3α2High 
population had a positive and negative population of Trop2 expressing cells 
whereas PC3α2Low cells were negative for Trop2 expression (I, Supplementary 
Figure 3C). The proliferation assay indicated that the DU145WTα2High cells had a 
reduced ability to multiply on collagen I, fibronectin and poly-L-lysine (PLL) when 
compared to the DU145WTα2Low cells (I, Figure 1E). This explains the 
enrichment of the cells possessing more α2 integrin and CD44 expression after the 
docetaxel treatment. Docetaxel targets cells at mitosis. Cells with a higher α2 
integrin expression divide less frequently and are therefore more resistant to drug 
treatment. These promising results justified continuingt the study to describe in 
depth the role of integrin α2β1 in cancer cell proliferation and survival by creating 
α2 integrin knockout lines for DU145 cells. 
5.3 The role of α2 integrin in DU145 cells (I) 
We successfully applied the CrispR/Cas9 system to target the α2 integrin at gene 
level in the DU145 cells and to create the knockout cell line DU145KO. The 
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knockout was confirmed by sequencing PCR amplified genomic DNA around the 
guide RNA binding area (I, Supplementary Figure 2). The DU145KO cells were 
used to generate two more cells lines: DU145KO+α2 cells, which have a rescued 
expression of α2 integrin, and DU145KO+vector line, integrin α2 negative cells, 
which carry an empty vector. The expression of α2 integrin was confirmed by 
Western blot (I, Figure 2B) and the presence of α2β1 on the surface of the 
DU145KO+α2 cells was determined by flow cytometry (I, Figure 2A). 
Additionally, the CD44 expression levels were controlled by flow cytometry in all 
cell lines as well. The results showed that the overexpression of α2 integrin did not 
affect the CD44 expression, indicating that these two stem cells markers are not 
regulated by each other. 
5.3.1 Integrin α2 regulates proliferation and resistance to 
docetaxel (I) 
Since α2β1 integrin signaling is thought to be more relevant in a 3D environment 
(Heino 2014) and DU145 cells are able to grow as spheroids in non-adherent 
conditions, the majority of the following work was carried out in a 3D spheroid 
system. The proliferation of the α2 positive DU145KO+α2 and the α2 negative 
DU145KO+vector cells was analyzed by measuring the increase in the DNA content 
in the spheroids. The α2 negative cells formed more compact spheroids and appeared 
smaller. However, the amount of DNA in the spheroid increased significantly faster, 
presenting a higher proliferation rate of the cells (I, Figure 2E). In the colony survival 
assay on collagen the DU145KO+α2 cells were significantly more resistant to 
docetaxel when compared to their α2 negative counterparts (I, Figure 2F), indicating 
the connection between reduced proliferation and increased survival. 
5.3.2 Integrin α2 regulates motility of cancer cells (I) 
The 3D spheroids consisting of α2 positive DU145KO+α2 cells had a loosened 
appearance compared to the α2 negative cell spheroids, and one of the explanation 
for this might be the increased motility of cells. To study the cell motility, the 
invasion of cancer cells through a matrigel coated transwell chamber was 
monitored. The results revealed that the DU145KO+α2 cells had a significantly 
higher invasion capacity compared to the α2 negative DU145KO+vector and the 
DU145WT cells (I, Figure 3A). The same assay was repeated with PC3α2High and 
PC3α2Low cells (I, Supplementary Figure 3D), where again α2β1 integrin high 
expressing cells had an advantage in their ability to invade through the matrigel 
transwell chambers. All the results supported the belief that the ability of cancer 
cells to invade is connected to their α2β1 integrin levels. To confirm that invasive 
prostate cancer cells have to express α2β1 integrin in order to move on or through 
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the collagen rich matrix, a spheroid-based migration and invasion assay were 
developed. 
Spheroids for the migration and invasion assay, composed of α2 positive 
DU145KO+α2 or α2 negative cells, were grown for 72 hours. For the migration 
assay, the spheroids were placed onto collagen I coated plates and for the invasion 
assay the spheroids were embedded into the collagen. The size of the surface area 
covered by cells was measured in both assays daily during 96 hours. The 
DU145KO+α2 cells had a significantly higher migration (I, Figure 3B) and 
invasion rate (I, Figure 3C) when compared to the α2 negative cells. 
5.3.3 Integrin α2β1 suppresses cell growth and promotes 
motility by activation of p38 MAPK. (I) 
Although integrin α2β1 does not have kinase activity itself, it still activates several 
signaling pathways. To understand α2 integrin specific signaling we used our α2β1 
integrin positive and α2 negative DU145KO+vector cells and measured the 
activation of FAK, ERK and p38MAPK (I, Figure 4A). The phosphorylation of all 
three proteins was significantly lower in the DU145KO+vector cells when 
compared to the DU145KO+α2 cells. These cells were plated onto a collagen I 
coated surface. The most significant effect was seen in the case of the p38 
phosphorylation. Therefore, we decided to clarify whether the inhibition of p38 
MAPK would induce an increase in DU145KO+α2 cells proliferation. The p38 
specific inhibitor SB203580 at a concentration of 10 µg/ml significantly increased 
the proliferation of the DU145KO+α2 cells. It also slightly increased the 
proliferation of the DU145KO+vector cells, but the difference was not statistically 
significant (I, Figure 4B). In addition, the p38 inhibitor had an enormous effect on 
the DU145KO+α2 cell migration (I, Figure 4C) and invasion (I, Figure 4D), 
indicating that the p38 MAPK pathway is important in DU145 cancer cell 
proliferation and motility regulation. 
5.3.4 Integrin α2β1 regulates genes previously associated 
with cancer progression (I) 
RNA sequencing was used to identify differentially expressed genes in DU145WT, 
DU145KO, DU145KO+α2 and DU145KO+vector cancer cells. Table 6 shows a 
list of genes expressed differentially in cells overexpressing α2 when compared to 
the knockout (DU145KO) and to the α2 integrin negative (DU145KO+vector) 
cells. Four biological replicates were used in order to increase the credibility of the 
analyzed gene list. The biological processes which were potentially affected by the 
differential gene expression between the α2 positive and the negative cells 
(DU145KO and DU145KO+vector) were identified (I, Figure5B). 
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Table 6.  List of genes most differentially expressed in α2 overexpressed DU145KO+α2 
cells when compared to DU145KO and DU145KO+vector cells indicated in fold 
change (FC).  
Gene symbol Description 
DU145KO+ 
α2 
vs DU145KO 
FC 
DU145KO+ 
α2 
vs DU145KO 
+vector FC 
CDH5 cadherin 5, VE-cadherin 7,646 67,204 
SCARA5 scavenger receptor class A, member 5 5,487 15,744 
ZNF853 zinc finger protein 853 5,386 12,975 
LGI1 leucine-rich, glioma inactivated 1 10,466 10,179 
JAM3 junctional adhesion molecule 3 2,059 6,726 
MMP-1 matrix metalloproteinase 1 8,76 5,268 
LINC00421 long intergenic non-protein coding RNA 421 4,952 4,816 
AMPH amphiphysin 2,47 4,501 
SVEP1 sushi, von Willebrand factor type A, EGF and 
pentraxin domain containing 1 
3,195 4,224 
FOXL1 forkhead box L1 2,543 4,057 
SLC18A2 solute carrier family 18 (vesicular 
monoamine transporter), member 2 
2,929 4,053 
DQX1 DEAQ box RNA-dependent ATPase 1 3,002 3,857 
ALX1 ALX homeobox 1 3,046 3,768 
CACNA1D calcium channel, voltage-dependent, L type, 
alpha 1D subunit 
2,029 3,417 
POM121 
L9P 
POM121 transmembrane nucleoporin-like 9, 
pseudogene 
2,273 3,293 
BEAN1 brain expressed, associated with NEDD4, 1 2,052 3,187 
KIF26B kinesin family member 26B 2,771 3,033 
DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 -2,35 -3,037 
VWA2 von Willebrand factor A domain containing 2 -3,49 -3,639 
CYP4F3 cytochrome P450, family 4, subfamily F, 
polypeptide 3 
-3,60 -3,046 
UBA7 ubiquitin-like modifier activating enzyme 7 -3,71 -3,252 
RASSF10 Ras association (RalGDS/AF-6) domain 
family member 10 
-4,20 -3,055 
SYK spleen tyrosine kinase -4,92 -4,519 
RBP1 retinol binding protein 1, cellular -5,18 -3,328 
C1orf116 chromosome 1 open reading frame 116 -6,62 -7,178 
PKP1 plakophilin 1 -6,66 -4,748 
CHD5 chromodomain helicase DNA binding protein 5 -7,14 -9,988 
SLC15A3 solute carrier family 15 (oligopeptide transp.) 
member 3 
-9,36 -7,288 
BST1 bone marrow stromal cell antigen 1 -9,88 -14,72 
SDC2 syndecan 2 -28,55 -11,773 
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Taking into account the previous connection to cancer progression described in the 
literature, 12 genes were selected (marked with light blue in the Table 6). To 
confirm the RNA sequencing results, the expression of these 12 genes in 
DU145KO+α2 and DU145KO+vector cells was analyzed using qPCR (I, Figure 
5D). 
The results indicate integrin α2 as a regulator of several genes associated with 
cancer progression, many of which have previously been related to prostate cancer 
or other malignancies. Substantial downregulation was seen in syndecan 2 
expression, which has been shown to be present in the majority of prostate cancers 
and is upregulated in high Gleason score cases (Popović et al., 2010). As α2β1 
integrin expression decreases in Gleason 3-5 prostate cancers (Mirtti et al., 2006) 
this opposite direction of syndecan 2 expression might have a role in vivo as well. 
Also, the expression of PKP1 and CDH5 genes was downregulated by integrin 
α2β1, both genes are transcribed to proteins with known tumor-suppressive 
properties. The diminished expression of PKP1 has been associated with a 
metastatic phenotype of prostate cancer (Yang et al., 2013). In contrast, the 
expression of two tumor suppressors, namely SCARA5 and LGI1, was induced, 
which is in accordance to the anti-proliferative action of integrin α2β1 in prostate 
cancer cells. The highest increase in gene expression was seen in cadherin 5, also 
known as vascular endothelial cadherin (CDH5 / VE-cadherin). Our group has 
previously shown the connection between α2β1 integrin and MMP-1 expression in 
other cells (Riikonen et al., 1995). Here, one of the remarkably upregulated genes 
in α2 positive cells was also MMP1 and since these cells had increased motility on 
the surface and in collagen I gel, the MMP1 degradation of collagen could be one 
reason for the ability of α2 positive cells to move through the collagen rich matrix 
as well as on its surface. We tested the MMP inhibitor, N-Isobutyl-N-(4-
methoxyphenylsulfonyl) glycyl hydroxamic acid (NNGH), in spheroid migration 
and invasion assays. The MMP inhibition, implementing 1 μM of NNGH, 
significantly reduced the migration of the DU145KO+α2 and DU145WT cells on 
collagen; however, invasion was not influenced by this concentration (I, 
Supplementary Figure 5). These results showed that MMPs are at least partially 
involved in the motility of the prostate cancer cells expressing α2 integrin. 
5.4 ECM in human prostate tissue (II) 
In order to study the ECM composition of the human prostate tissue, a 3 step 
matrix extraction protocol, developed initially for the isolation of the ECM from a 
human aorta (Didangelos et al., 2010) was applied. Based on the proteomics data 
obtained with mass spectrometry (MS), altogether 120 reliable recognitions were 
observed and categorized as ECM proteins. MS data enabled the composition of 
ECM to be established in the human prostate (II, Figure 4A, Supplementary Table 
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S3). The prostate loose connective tissue was composed of fibril forming collagens 
I, III and V, and fibril-associated collagens XII and XIV, in addition fibril-binding 
proteoglycans decorin and biglycan. BM components, such as collagen IV chains 
α1 and α2, laminin chains α2, α4, α5, β1, β2, and γ1, nidogen 1and 2, perlecan, 
fibulin 1, and collagens XV and XVIII were also recognized. Fibronectin, tenascin 
C and XB, collagen VI, fibulin-1 and -2, and proteoglycans lumican and 
osteoglysin were identified in several samples. In order to study in depth the cells 
contributing to the ECM production and the possibility to use ECM in vitro we 
continued with isolation of fibroblastic cells from human prostate tissue. 
5.5 Prostate-derived fibroblastic cells (II, III) 
Prostate-derived fibroblasts were isolated from cancerous and non-cancerous tissue 
samples from radical prostatectomy specimens obtained from Turku Prostate 
Cancer Consortium in collaboration with Auria Biobank and the Pathology unit of 
Turku University Hospital. 
5.5.1 Fibroblasts become activated by culture conditions (II) 
During the study 27 cell-lines were created of which cells had the characteristic 
appearance of fibroblastic cells in culture. To confirm their mesenchymal origin, 
cells were immunostained for widely used marker proteins. Vimentin, α-SMA and 
FAP, together with negative staining for cytokeratin, were used as markers for the 
fibroblasts and activated fibroblasts. The created fibroblast cell-lines were positive 
for vimentin, α-SMA and FAP, independently from the cancerous or non-
cancerous origin (Figure 6). The expression levels of the two activation markers, α-
SMA and FAP, correlated with each other in relative mRNA levels measured by 
the qPCR analysis (II, Figure 1D-E). A minor tumor or non-transformed epithelial 
cell contamination was observed (II, Figure 1B-C); however, it was considered not 
to interfere with further studies. 
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Figure 6.  Cell cultures initiated from human prostate tissue showed the positive staining for 
mesenchymal marker vimentin and activated fibroblast marker α-SMA. Scale bar is 
20 µm. 
5.5.2 Fibroblasts produce functional ECM (II) 
Fibroblasts were allowed to produce ECM proteins on the plastic cell culture dish 
during the 7 days cultivation in the presence of ascorbic acid (aa, 50 µg/ml) in 
order to provide the performance of prolyl hydroxylases and the synthesis of stable 
collagens. The presence of the ECM proteins was identified by 
immunofluorescence staining of the abundant matrix proteins fibronectin and 
collagen I (II, Figure 2A). Apparent staining was confirmed in both conditions with 
or without cells after the hypotonic lysis of the fibroblasts. The fibrillary structures 
in the ECM were visualized by scanning electron microscopy (SEM) (II, Figure 
2B) 
The cell-free ECM was subjected to further studies with the DU145 and PC3 
prostate cancer cells. Cancer cells attached and spread on the ECM as on the 
collagen I or fibronectin coated plates. We discovered that the DU145 cells show a 
significantly decreased proliferation rate on the ECM when compared to 
fibronectin and collagen I coated surfaces (II, Figure 2C).  
ECM proteins produced in 2D monolayer cultures by 6 cancerous and 
accordingly 6 non-cancerous fibroblastic cell-lines were collected. After collection 
the ECMs were subjected to mass spectrometry analysis to identify the synthesized 
ECM proteins. We identified 164 matrisome proteins which have been listed as 
“core matrisome” or “matrisome associated” in the Matrisome database (Naba et 
al., 2012). The detected 132 proteins out of 164 were identified in the produced 
matrix at least in one of the cell-lines in both groups (II, Supplementary Table2). 
This finding is at least partially related to the fact that both cancer associated 
fibroblasts (CAFs) and non-cancer-derived fibroblasts were activated in the cell 
culture conditions. Thirteen proteins were identified in the CAF produced matrix 
and not present in the non-cancerous matrix. Nineteen proteins were solely 
identified in some of non-cancerous fibroblasts matrix, without identification in the 
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CAF matrix. However, these differences were not statistically significant once 
compared between the groups defined as tumor and non-cancerous fibroblasts. Our 
results are in accordance with the outcome of studies analyzing and describing the 
considerably high person-to-person protein expression variation. Furthermore, even 
the fibroblasts isolated from the same patient can be remarkably heterogeneous in 
their gene expression pattern despite having been demonstrated to keep their gene 
expression for several passages in cell culture (Chang et al., 2002).  
We also analysed the expression of three matrix proteins at mRNA levels, 
namely collagen α1 (I), collagen α1 (III), and periostin (II, Figure 3A-C). The 
mRNA levels do not always reflect the actual protein level in matrix, but based on 
this it is possible to investigate their expression. We noted that collagen α1 (III) 
mRNA levels were lower in 5 out of 6 cases in the CAFs compared to the non-
affected fibroblasts in the same prostate (P = 0.026). We also compared the 
expression of these matrix proteins with the activation level of the fibroblasts and 
discovered that collagen α1 (I) or α1 (III) mRNA levels did not correlate with α-
SMA mRNA levels (II, Figures 3D-E), but periostin and α-SMA had a statistically 
significant correlation (P = 0.005) (II, Figure 3F). Based on our results all 
fibroblasts become activated in the cell-culture conditions, but they may preserve 
some properties related to the origin of the tissue, i.e. the CAFs versus normal 
tissue fibroblasts. To understand better how the 2D cell culture conditions changed 
the matrix produced by fibroblasts, we decided to use a fibroblastic cell-line (II, 
Table 1, Patient 2 cancer location isolated fibroblasts) in a 3D spheroid culture 
system with and without the DU145 prostate cancer cells (II, Figure 5). The results 
revealed that only 62 proteins were shared within the matrix produced by same 
fibroblastic cell-line in the monolayer and in the spheroid (II, Figure 6A). 
Surprisingly, we identified 86 ECM proteins specific to either the 2D or 3D culture 
condition. Most differences were in the group of “ECM regulators”, followed by 
“secreted factors” and then “glycoproteins”. The formation of basal lamina was 
alternatively regulated since collagen VII, laminin α3 and γ2 chains were identified 
only in spheroids. Lysyl oxidase (LOX) was only found in the spheroids, 
suggesting that the assembly of collagen fibrils is induced in the 3D culture system. 
5.5.3 ECM components produced by cancer cells or by 
fibroblasts and in co-culture (III) 
Based on mass spectrometry and proteomics analysis, 64 matrisome proteins were 
identified in the spheroid cultures for the DU145 or PC3 prostate cancer cells, 
indicating that without fibroblasts cancer cells synthesize little ECM. The DU145 
cells did not express core matrisome structural proteins when cultivated alone, 
whereas PC3 cells did produce the laminin chains alpha3, beta3 and gamma 2 
(known as LN332/ laminin-332), as well as perlecan and collagen type VI (III, 
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Supplementary Table 1.) Thirty-two matrisomal proteins were shared between the 
DU145 and PC3 cells, 4 proteins were identified only in the DU145 matrisome and 
the PC3 cells had 28 unique matrix proteins (III, Figure1A, and Supplementary 
Table 1.). The proteins common between the DU145 and PC3 cells could be 
categorized into several regulatory protein families, like cathepsins and ADAM 
proteinases, annexins, S100 and galectin family members and procollagen lysine 
hydroxylases (PLOD) (III, Supplementary Table 1.). Interestingly, the presence of 
PLODs in the ECM is in accordance with the recently reported extracellular 
function in lung cancer (Y. Chen et al., 2016). These findings propose that collagen 
may be modified in the extracellular space, not only in endoplasmic reticulum. 
PLOD2 is required for collagen fiber formation and alignment, and through this 
function it contributes to ECM stiffening. The overexpression of PLOD2 leads to 
fibrosis (Gilkes et al., 2013). 
The experimental data from the second study described fibroblasts to be the 
main cell type predominantly synthesizing the core ECM proteins. Another 
fibroblast cell-line generated (II, Table 1, Patient 3 cancerous tissue sample) was 
cultured in the spheroids alone or alongside the fibroblasts/DU145 and 
fibroblasts/PC3 cells (III, Figure 1B, Table 2). In the fibroblast spheroids, most of 
the collagenous ECM components were identified: both α1 and α2 chains of fibril 
forming collagen I, fibril associated collagen XII and beaded filament forming 
collagen VI, as well as fibronectin, tenascin C and decorin. The fibroblasts alone 
express laminin β1 and γ1 chain (III, Supplementary Table 1.); however, in the co-
culture with cancer cells a prominent accumulation of the laminins (α3, α5, β2 and 
β3) was observed (III, Table 2.). The synthesis of BM components, namely 
perlecan and collagen XVIII had increased expression in both the fibroblast/DU145 
and fibroblast/PC3 spheroids (III, Table 2.). The downregulation of certain ECM 
proteins was identified in the co-cultures, particularly fibrillin-2, fibulin-1 and 
collagen XIV. HGF was identified only in the fibroblast spheroids,but it remained 
undetectable in the co-culture samples (III, Table 2.). 
5.5.4 Co-culturing of fibroblasts with DU145 or PC3 cells 
leads to enhanced ECM proteins degradation (III) 
Although the PC3 cells could independently produce some BM components in the 
spheroid cultures, the DU145 cells were not capable of doing so. However, the co-
cultivation of cancer cells along with fibroblasts lead to an accumulation of the 
proteins required to form the BM (III, Table 2). Concurrently, the degradation of 
the ECM proteins seemed to be enhanced in the co-culture spheroids. The 
accumulation of laminin-332 and collagen XVIII noticed in the MS and proteomics 
analysis was controlled by Western blot. Using an anti-human laminin-332 
antibody confirmed the accumulation of this BM component and also revealed 
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several smaller bands detected only in the fibroblast/DU145 and fibroblast/PC3 
spheroid samples (III, Figure 3). The collagen XVIII was significantly processed 
into endostatin, as the peptides identified in the MS belonged to the endostatin part 
of the protein and enhanced endostatin protein bands were detected also by 
Western blot (III, Figure 4). The active degradation of laminin-332 into smaller 
peptides was also noticed in Western blot analysis. The enhanced turnover of the 
ECM, detected in co-cultures, is probably mediated through the co-operation of 
several degrading enzymes. Presumable candidates include regulators such as 
MMP14, expressed by fibroblasts, or cathepsins and the ADAM family MMPs 
produced by cancer cells. Utilizing broad MMP inhibitor and MMP-14 specific 
inhibitor revealed that MMPs are needed for invasion of DU145 cancer cells in 
“out of spheroid” assay, however MMP inhibition did not affect the formation of 
laminin-332 and endostatin containing fragments. Endostatin formation was 
decreased when cells in spheroids were treated with cathepsin L inhibitor.  
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6 Discussion and General 
Perspectives 
6.1 Integrin α2β1 regulates proliferation, invasion and 
gene expression of prostate cancer cells 
The complexity of integrin α2β1 in prostate cancer is reflected by the controversial 
findings that integrin α2β1 is downregulated during prostate cancer progression 
(Bonkhoff, Stein, and Remberger 1993b; Mirtti et al., 2006) and at the same time is 
a cancer stem cell marker (Collins et al., 2005; Trerotola et al., 2010). Previous 
works have also suggested the importance of integrin α2β1 in prostate cancer cell 
metastasization into bone (Sottnik et al., 2013; Ricci et al., 2013). These assertions 
do not fit perfectly to the traditional tumor progression cascade, unless the cancer 
stem-cell theory is included. This theory suggests that most invasive cells have 
stem cell properties and are resistant to all environmental challenges. Questions 
regarding the role of integrin α2β1 in prostate cancer cells and its ability to regulate 
gene expression and motility have previously remained unanswered. The findings 
obtained within this current doctoral thesis significantly extend the previously 
known properties of integrin α2β1 in cancer cell motility and as additional features, 
also include the regulation of proliferation and the control of gene expression. 
6.1.1 Docetaxel treatment enriched the population of DU145 
cells with higher expression of α2β1integrin and CD44 
The outcome of our first attempts to study the role of the ECM or its certain 
components as a protective factor against the chemotherapeutic drug docetaxel did 
not agree with some previously published data (Thomas et al., 2010), since the 
ECM had no direct effect on cell survival. However, other studies have clearly 
indicated integrin-mediated protection against chemotherapeutics. In one study, 
integrins α2β1 and α5β1 expression on MDA-MB-231 breast cancer cells was 
shown to decrease apoptosis induced by paclitaxel. However, these receptors did 
not have the same effect on MDA-MB-435 cells. In the last case α6β1 integrin and 
the attachment to laminin was indicated to be responsible for a reduction in 
paclitaxel induced cell death. In both cell lines the integrins were shown to activate 
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PI3K/Akt signaling, which induced the expression of Bcl-2 and inhibited the 
release of cytochrome c to mediate survival (Aoudjit and Vuori 2001). In another 
study, integrin α2β1 expression on T cell acute lymphoblastic leukemia (T-ALL) 
cells and attachment to collagen I promoted survival against doxorubicin through 
the activation of MAPK/ERK (Naci et al., 2012). These results indicate that the 
integrin-mediated attachment and survival enhancing effects may be receptor and 
cell type specific. Although, in our study the protective effect of ECM proteins on 
docetaxel induced cell death was not noted, we decided to study the surviving cells 
in more detail. We discovered the enrichment of the integrin α2β1 and CD44 high 
cells among surviving cells. One of the mechanisms of cancer stem like cells to 
survive cytotoxic drug treatments could be the rapid efflux of drugs. CD44 has 
been shown to participate in the induction of MDR1 expression and the regulation 
of drug resistance (Misra et al., 2005). Another explanation could be the decreased 
proliferation of cells with a high expression of integrin α2β1 and CD44 which 
provide a better survival against drugs that target highly proliferative cells. To test 
this hypothesis, DU145 cells were sorted into high and low α2β1 integrin 
expressing cells and their proliferation and survival were tested. The results created 
a link between the higher expression of integrin α2β1 and better survival. 
Nonetheless, it was impossible to claim whether the higher expression is the reason 
or the consequence. To test the integrin α2β1 induced stem cell characteristics of 
DU145 cells Crispr/cas9 technology was applied. 
6.1.2 Proliferation and motility of prostate cancer DU145 
cells is regulated by α2β1 integrin through p38 MAPK 
pathway 
The study revealed that integrin α2β1 decelerates proliferation since 
DU145KO+vector cells had increased proliferation compared to α2 positive 
DU145KO+ α2 cells. A decrease in the proliferation of α2β1 integrin expressing 
cells could be the reason for the decrease in their population during prostate cancer 
progression and would explain the previous report by Mirtti et al, 2006.  
Still, the α2 positive DU145KO+ α2 cells had remarkably increased motility 
compared to the α2 negative cells, which demonstrates the importance of α2β1 
integrin expression in a metastatic cancer cell population. It has been shown that 
PC3 cells with suppressed or reduced α2β1 integrin on cells have significantly less 
tumorigenic potential and metastases capability (Ryu, Park, and Lee 2016; Lee et 
al., 2009). Furthermore, we discovered that the p38 MAPK pathway is one main 
regulator of invasion and proliferation downstream from α2β1 integrin in DU145 
prostate cancer cells. The regulation of DU145 cell motility by p38 has also been 
studied earlier (Shen et al., 2010). Moreover, we showed that the inhibition of p38 
MAPK with specific inhibitor SB203580 significantly increased the proliferation 
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of α2 integrin positive cells, whereas the treatment on α2 negtaive cells was 
ineffective. Also, the treatment with an inhibitor resulted with the diminished 
invasion capability of α2 positive cells to the level of α2 negative cells. These 
findings warrant studying α2β1 integrin-targeted therapy as a potent approach to 
treat chemotherapy resistant and metastatic prostate cancer cells. 
6.1.3 Integrin α2 regulates gene expression related to 
cancer progression  
The α2β1 positive cells had a significantly higher MMP-1 expression. This is in 
accordance with earlier study where Riikonen et al. showed that α2β1 integrin 
induces the expression of MMP-1. Considering the motile phenotype of α2 integrin 
positive cells, high MMP-1 expression enables the local degradation of the ECM to 
further facilitate dissemination. 
The induction of cadherin 5 (CDH5) expression was also observed in α2 
integrin expressing cells compared to knockout cells. The cell-cell adhesion 
proteins, cadherins, have been shown to be dysregulated in many malignancies. 
Cadherin 5, also known as vascular endothelial cadherin (VE-cadherin) is not 
expressed in normal epithelium, but is expressed in several tumors. Cancer cells 
expressing cadherin 5 might easily take part in vasculature mimicry (VM). VM is 
described as cancer cells interacting with endothelium or even replacing 
endothelial cells which form mosaic vessels. VM vessels are clinically significant 
and increase the risk of metastatic disease. In gastric cancer CDH5 is a marker for 
poor survival (Higuchi et al., 2017) and the phosphorylation of cadherin 5 in a co-
culture of breast cancer cells with HUVECs was induced by α2β1 integrin (Haidari 
et al., 2012). In addition it has been proposed that the matricellular proteins 
produced by CAFs, the proteolytic processing of laminin-332 and the dense 3D 
collagen-network existing in the TME could trigger the formation of VM vessels 
(Eble and Niland 2019). 
Concomitantly, integrin α2β1 downregulates several tumor suppressors, 
including plakophilin1 (PKP1), a protein participating in desmosome formation. 
Syndecan 2 was up-regulated in α2 integrin knockout cells. In high Gleason score 
prostate cancers, where overall expression of integrin α2β1 is decreased, syndecan 
2 is known to be increased (Popović et al., 2010). The bi-dierctional expression of 
syndecan 2 and integrin α2β1could be studied in more detail.  
The majority of genes (7 outr of 12) that were up or down regulated by the 
expression of integrin α2β1 on the cell surface, were also regulated by integrin 
α2β1 binding to its ligand, collagen I. However, when α2 positive and negative 
cells were plated on collagen and fibronectin some of the effects were evident on 
both surfaces leaving the option that α2β1may also have ligand independent 
functions. It has been proposed earlier that integrins may have ligand independent 
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functions (Ferraris et al., 2014) and that α2β1integrin with a loss-of-function 
mutation at α2E336A is able to induce FAK phosporylation and downstream 
signaling (Salmela et al., 2017). However, the ligand independent functions of 
integrins have not been studied in detail.  
Collectively, based on our results, α2β1 integrin expression on cancer cells 
contributes to the gene expression pattern influencing tumor evolvement. 
6.2 Prostate fibroblasts mainly produce the 
components of ECM, crosstalk with cancer cells 
enhances remodelling 
Alterations in the ECM composition and organization have been proposed to 
induce tumour burden and dissemination (Erler and Weaver, 2009; Rowe and 
Weiss, 2009; Lu et al., 2012). CAFs as common cells in cancerous stroma are 
known to synthesize and organize the ECM in the TME. Interestingly, it was 
shown that another integrin, namely α3β1 with its interaction to laminin-332 
maintains the CAF phenotype and facilitates the invasion of pancreatic 
adenocarcinoma cells (Cavaco et al., 2018). Based on our results, prostate-derived 
fibroblasts in in vitro cell culture are able to synthesize many ECM proteins. These 
include several structural proteins such as collagens, FN, tenascin C, and also GFs 
embedded into the matrix, for example FGF2 and HGF. In addition the fibroblasts 
in the spheroid culture were able to synthesize some components of the BM, for 
example laminin β1 and γ1 chain, collagen IV and XV. Prostate cancer cell lines 
DU145 and PC3 differ in their ability to produce ECM proteins. When DU145 
cells are unable to synthesize any core matrisome proteins, then the PC3 cells can 
produce several components of the BM and many matricellular proteins. However, 
in co-cultures of cancer cells with fibroblasts, ECM protein synthesis is increased 
and it seems that the cells collectively produce all the components needed for the 
BM formation. The induced expression of several laminins, perlecan and collagen 
XVIII was observed in both the DU145 and PC3 co-cultures with fibroblasts. 
Laminin-332 protein expression has been reported to be diminished in prostate 
cancer. The same report, however, indicates that the corresponding mRNA levels 
remain normal (Hao et al., 2001). In the in vitro system we not only saw the 
induction of laminin-332 protein expression, but simutanously the degredation of 
the BM components laminin-332 and collagen XVIII were also observed. An 
intensive degradation of proteins rather than reduced gene expression may explain 
the findings by Hao et al., 2001. Depending on the cancer type, laminin-332 has 
been shown to be either down or up regulated with the opposite effect on cancer 
cell dissemination. In colorectal carcinoma, breast cancer, prostate carcinoma, and 
oral squamous cell carcinoma (SCC) the protein levels of laminin-332 are 
diminished and these tumors are thought to have a tumor suppresive role. Whereas, 
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in pancreatic carcinoma, lung adenocarcinoma, malignant glioma, gastric cancer, 
SCC elevated laminin-332 protein levels have been reported (Tsuruta et al., 2008). 
In some of these cancer types elevated laminin-332 is connected with the increased 
dissemination of cancer cells. Degradation of basement membrane proteins can 
produce biologically active peptides which can regulate behavior of malignant cells 
and other cells present in local microenvironment. Our results indicated that MMPs 
are needed for dissemination of DU145 cells in “out of spheroid” assay, but are not 
responsible for formation of endostatin and laminin-332 fragments. Whereas 
cathepsin L, expressed by DU145 and PC3 cells is responsible at least partially for 
formation of endostatin containing fragments from collagen XVIII.   
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7 Conclusion and Future Prospects 
The tumor microenvironment, including malignant cells as well as activated 
stromal and immune cells and the scaffolding ECM, has been proposed to 
contribute to cancer progression. This thesis provides new knowledge about the 
ECM synthesized by cancer associated fibroblasts and the adhesion molecule 
integrin α2β1 in human prostate cancer. This thesis work demonstrates the 
following findings: 
I. Integrin α2β1 is essential for cancer cell dissemination in the collagen rich 
ECM  
II. Integrin α2β1 regulates the proliferation and motility of DU145 prostate 
cancer cells through the p38 MAPK pathway 
III. The ECM is mainly produced by fibroblast cells in in vitro cell culture 
conditions and in vivo in human prostate 
IV. The co-culture of cancer cells with activated fibroblasts enhances the 
synthesis and proteolytic processing of ECM proteins. 
Integrin α2β1 is a marker protein of both prostate stem cells and prostate cancer 
stem cells. The adhesion protein α2β1 mediates the cell attachment to collagens 
and to several other ECM proteins. The attachment to ECM proteins through the 
integrin regulates the behavior of the cell including its processes such as 
proliferation, motility and survival.  
The results obtained in this thesis project explain the previous controversy 
related to the role of α2β1 integrin in prostate cancer. Firstly, the finding that 
integrin α2β1 inhibits prostate cancer cell proliferation explains why the bulk of 
non-tumorigenic cells in tumors have reduced levels of integrin α2β1 expression. 
Secondly, integrin α2β1 seems to protect the phenotype and survival of cancer stem 
like cells. And thirdly, the most important cells for cancer progression and 
dissemination are tumorigenic cancer stem cell like cells, which remain integrin 
α2β1 positive. 
ECM is a complex scaffold and reservoir of growth factors and active peptides. 
In tumorigenesis, the ECM is continuously remodeled. Cancer cells use matrix 
proteins to move and release growth factors to induce their own proliferation. The 
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results support the findings that fibroblasts are the main source of ECM proteins in 
the in vitro models used in this thesis. Due to the restrictions of the cell culture 
models, the composition of the ECM in vitro is slightly different from the ECM 
found in vivo in the human prostate. However, based on the similarity of the core 
matrisome components it could be said that fibroblasts are the main source of ECM 
proteins also in human prostate tissue. The effects of the insoluble matrix on cancer 
cells have been investigated less extensively. This thesis aimed to bring new 
knowledge into this topic also. 
In the future, the 3D co-culture model applied extensively in this thesis could 
be used to investigate the ECM in other cancer types. It would be interesting to 
study whether cancer stem cell markers could be used to specifically target this 
population of cancer cells or could certain matrix proteins be used to target a 
microenvironment. This could improve the cancer treatment options already 
available.  
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